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C Stellingen behorende bij het proefschrift: 
cfor 11munity-Acquired Pneumonia: monitoring and modulation of the host response 
.._ ______ '-"r"'�-u.=�l,l;-h obstructief longlijden is geen risico verhogende co-morbiditeit bij een buiten het 
ziekenhuis opgelopen longontsteking (dit proefschrift) 
Prednisolon naast antibiotica bij buiten het ziekenhuis opgelopen longontstekingen leidt niet 
tot een beter klinisch herstel, maar geeft wel meer kans op laat therapie falen (dit 
proefschrift) 
Het gebruik van C-reactive protein om het beloop van een buiten het ziekenhuis opgelopen 
longontsteking te monitoren is af te rad en als tegelijkertijd prednisolon wordt gebruikt ( dit 
proefschrift) 
D-dimeren hebben geen toegevoegde waarde als prognostische biomarker in patienten met 
een buiten het ziekenhuis opgelopen longontsteking maar kunnen wel diagnostische 
onzekerheid brengen (dit proefschrift) 
Als paardenmiddel heeft prednisolon weinig effect op humane longontstekingen. 
Het feit dat er veel meer review artikelen zijn verschenen dan oorspronkelijke onderzoeken 
over corticosteroiden bij longontstekingen bewijst dat medici graag praten over zaken waar 
ze weinig van weten. 
''Those who cannot learn from history are doomed to repeat it." (George Santayana) 
De term korte klinische beoordeling (KKB) is waarschijnlijk bedoeld om assistenten in 
opleiding al vroeg in hun carriere te laten wennen aan nutteloze maatregelen in de zorg. 
"Als er meer dan vijftig jaar nodig zijn om iets te bewijzen, dan zal het niet zo zijn" (vrij naar 
A. Soomers, internist-intensivist, MCA) 
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The first description of pneumonia occurred in the classical Greek era. Hippocrates (460-370 B.C) 
was the first to describe the signs and symptoms of pneumonia, although signs of pneumonia were 
observed in mummified persons from 1250-1000 B.C. 1;2• The description of pneumonia given by 
Hippopocrates was as follows: 
Peripneumonia, and pleuritic affections are 
to be thus observed: If the fever be acute, and 
if there be pains on either side, or in both, 
and if expiration be if cough be present, and 
the sputa expectorated be of a blond or livid 
color, or likewise thin, frothy, and florid, or 
having any other character different from 
the common... When pneumonia is at its 
height, the case is beyond remedy if he is not 
purged, and it is bad if he has dyspnoea, and 
urine that is thin and acrid, and if sweats 
come out about the neck and head, for such 
sweats are bad, as proceeding from the 
suffocation, rales, and the violence of the 
disease which is obtaining the upper hand. 
Hippocrates of Kos (1638). Engraving by Peter Paul Rubens 
Pneumonia - notably, community-acquired pneumonia (CAP) - has been a scourge for mankind. 
CAP has been a leading cause of death and of considerable morbidity3;4• Mortality is highest among 
infants and in the elderly especially in those with co-morbidities5 • In the Netherlands, the incidence 
of pneumonia was 54/10.000 in 2008, with the highest incidence in the very young (0-4 years) and 
the very elderly (> of�85 years) (http://www.nivel.nl/pdf/Rapport-cmr-2008.pdf). 
Pneumonia is an inflammation of the parenchyma of the lung(s), most often caused by bacterial, 
viral or fungal agents. The diagnosis is made on clinical symptoms and signs (fever, shortness of 
breath, sputum expectoration, pleurisy and auscultatory findings consistent with pneumonia) in 
combination with a new or progressive consolidation on the chest radiograph (figure 1). 
Streptococcus pneumoniae is the most common cause of CAP, accounting for 22 % to 3 5 % of cases, 
followed by Mycoplasma pneumonia, Legionella pneumophila, Chlamydophila pneumoniae and 
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viral infections6•9• The incidence of these pathogens varies across studies, due to differences in 
microbiological evaluation of patients with CAP and differences in study populations and study 
settings. Pursuing an aetiological diagnosis with intensive microbiological investigation in patients 
with CAP increases the incidence of pathogens identified 1°. 
Figure 1. Chest radiograph (PA) of a patient with community-acquired pneumonia. 
The inflammatory and coagulation cascades in infection 
The host response in infections such as CAP is complexll;12• In response to invading pathogens, 
there are several defence mechanisms in the airways and lungs. The bronchial epithelial lining with 
its tightly bound cells, ciliae and mucus secretion forms a tight physical barrier as first line of 
defence, assisted by coughing and sneezing. The next line of defence is the innate immune system 
which constitutes a first-line antimicrobial defence. The innate immune system incites an acute 
phase response which is mediated by pattern recognition molecular receptors (PRR). PRRs react 
to pathogen-associated molecular patterns (PAMP). These are carbohydrates, proteins and lipid 
molecules expressed by bacteria and fungi, but not by the host itself. The acute phase response is 
characterised by the release of mediators which have several effects ( table 1). The adaptive immune 
responses constitute a complex and intertwined system of T-cell mediated cellular immunity and 
B-cell mediated humoral immunity (figure 2). Apart from inflammatory and compensatory anti­
inflammatory cascades, coagulation and platelet activation cascades as well as their counteracting 
anti-coagulative pathways are activated13•16• The host also uses another defence mechanism in 
response to infection; inflammasomes. Inflammasomes are multi-protein complexes who in 
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response to PRRs can activate caspase-117 • The activation of caspase-1 results in release of the pro­
inflammatory cytokines interleukin-1� (IL-1�) and interleukin 18 18 • Both these cytokines play an 
important role in the host response to pathogens as S. pneumoniae and P. auruginosa19 22• Another 
effect of caspase-1 activation is pyroptosis. Pyroptosis restricts intracellular bacteria growth and 
dissemination by destroying infected cells and is an effective mechanism to protect the host from 
infection2P4. In the context of this thesis the focus will be mainly on the responses of innate 
immune system and the coagulation pathways. 
Table 1. Several acute phase proteins and their effects 
we-reactive protein 




Plasminogen activator inhibitor 
IL-1 receptor antagonist 
Opsonisation, complement activation, immunomodulation 
Leucocyte activation chemotaxis, phagocytosis 
Copper transport 
Iron transport 
Activation of fibrinolysis, complement, clotting 
Inhibition of plasminogen 
IL-1 antagonism 
Figure 2. Overview of the immune and coagulation system in lower respiratory tract infections. 
Pathogen 
Innate immune system Acquired immune system 
Acute phase response ± 
Antigen+ 
• C-reactive protein 




Chemotaxis ....... Pathogen ..... Cellular immunity {CD-8 T-lymfocytes) 
Phagocytosis ....... clearance 
• Plasminogen 
• PAI 





Cytokines and chemokines in CAP 
Alveolar macrophages (AM) are important in clearing the invading pathogens via phagocytosis. 
Phagocytosis by AM can be enhanced by means of opsonisation. TNF-a and IL-1� released by AM 
act as pro-inflammatory cytokines while interleukin-8 (IL-8) and Granulocyte-Colony Stimulating 
Factor ( G-CSF) have a chemotactic and activating effect on polymorphonuclear neutrophils 
(PMN). The recruitment of immune system cells is also enhanced by chernokines, which serve as 
chemoattractants25 • The majority of these chemokines are pro-inflammatory and unlike other 
cytokines are often selective for specific cell types. Interleukin-10 (IL-10) is an anti-inflammatory 
cytokine produced by AM, monocytes, PMN and T-lymfocytes26• IL-10 is also an important 
cytokine in downregulating the pro-inflammatory cascade. The intensity of the inflammatory 
response is a balance between the pro-inflammatory cytokines (e.g., IL-1� and TNF-a) and the 
anti-inflammatory cytokines (e.g., IL-10 and IL-1RA)14• 
In several studies the levels of pro-inflammatory and anti-inflammatory cytokines in patients with 
severe CAP have been measured27-29• In these patients elevated levels ofTNF-a and IL-6 are found 
with slightly more elevated levels in non survivors than in survivors (Figure 3). In the study by 
Monton et al.29 survivors treated with corticosteroids had lower TNF-a and 11-6 levels, suggesting 
that corticosteroids may attenuate the inflammatory response. 
Figure 3. Serum levels ofTNF-a and IL-6 in patients with severe CAP in different studies, 


















There is an bidirectional interaction between activation of the inflammatory cascade and activation 
of the coagulation system 16• Derangement of coagulation is driven by tissue factor mediated thrombin 
formation next to dysfunction of the physiological coagulation mechanisms. Tissue factor expression 
is mostly dependent on IL-6. The activation of the coagulation leads to enhanced fibrin formation 
and depressed fibrinolysis30• There are several ways in which the host response to the increased 
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coagulant state. Tissue factor pathway inhibitor (TFPI) is an anticoagulant protein3 '. Next to its 
anticoagulant properties, TFPI also has anti-inflammatory properties, most likely by limiting 
thrombin generation. Furthermore activated Protein C, antitrombin and Plasminogen Activator-1 
have anticoagulant effects3H4.The coagulation derangement can be intervened, however the clinical 
value of these interventions is not well defined33;35-3s. As a simple marker of increase fibrin production 
or decreased fibrinolysis D-dimer levels, fibrin degradation products, can be used. Several studies 
have examined the prognostic implications of D-dimer testing in patients with CAP39-4•. 
Corticosteroids and infection 
Corticosteroids have strong immunomodulatory effects. These effects fall into three methods of 
action. The first method is a direct genomic effect by increasing or decreasing gene transcription. 
The second method is a indirect genomic effect. By blocking nuclear factor-KB the transcription of 
cytokines, and chemokines is stimulated. The third method of action is a non-genomic effect. 
Corticosteroid signalling is activated by membrane-associated receptors and second messengers42• 
These effects translate into decreased pro-inflammatory cytokine release and increased anti­
inflammatory factors (figure 4). The theory of attenuated inflammatory response by corticosteroids 
has led to many randomised clinical trials in sepsis and septic shock43 • Although corticosteroids 
have been widely used in sepsis and septic shock and its use is incorporated in the Surviving Sepsis 
Campaign, the evidence is still not convincing8;44;45• 
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Adhesion molecules (ICAM-1, E-selectin) 
More than half a century ago Wagner et al46 performed the first clinical trial of adjunctive corticosteroid 
treatment in patients with CAP. In their study there was no apparent benefit of corticosteroids except 
a faster defeveresence. In the subsequent decades other studies also did not find any benefits of 
adding corticosteroids to the treatment of CAP4M8• In one randomised clinical trial in mechanically 
ventilated patients with CAP, the authors reported a benefit for steroid treatment. Length of stay was 
shorter, oxygenation improved and mortality was lower in the group of patients treated with 
hydrocortisone compared to standard care 49• One possible explanation for the beneficial effects of 
corticosteroids is the existence of relative adrenal insufficiency in severely ill patients50-53• Whether 
this phenomenon also occurs in less severely ill patients with CAP remains uncertain54 
Improving outcomes 
Improving clinical outcomes in patients with CAP is a worthy goal to pursue for any respiratory 
physician. Several factors contribute to clinical outcome in patients with CAP55;56• The role of 
COPD as risk factor for CAP-related death is debatable57-59• One should expect that the co­
morbidity COPD especially in those patients who are admitted in the ICU is an important risk 
factor for mortality. However, COPD is associated with an increased risk of hospitalisation but is 
has not been recognised as a risk factor in the Pneumonia Severity Index60;61 • Identification of 
patients with COPD in trials of patients with CAP can be difficult. The definition of COPD 
according to the GOLD guidelines require spirometric data. In the studies by Rello et al. 57 en 
Restrepo et al.58 identification of patients with COPD was done by proxy parameters as inhaled 
corticosteroids or by history, making the incidence of COPD probably less reliable. 
Biomarkers 
A biomarker is, as defined by the National Institute of Health, a characteristic that is objectively 
measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention 62• With the use of biomarkers the care of 
patients with CAP may be improved. The use of C-reactive protein (CRP) can help to monitor 
response to treatment in patients while procalcitonin (PCT) may reduce the length of antibiotic 
treatment in these patients groups63;64.Several other biomarkers also have shown to have prognostic 
value in patients with CAP9;65 • However, none of these biomarkers have made its appearance in 
severity scores for patients with CAP, which may be partial due to their test characteristics or to 
doctor's attitude towards the use of these biomarkers. Furthermore, the expression of these 
biomarkers may not be the same in all patients with CAP. 
Anaemia and inflammation 
Ten to thirty percent of the patients with CAP have an anaemia on admission66;67• Haemoglobin 
level itself is not incorporated as a risk factor in the PSI score but the closely related haematocrit 
is60• In the PSI derivation cohort 10% of the patients had a haematocrit < 30%. So, anaemia does 
have a effect on outcome in patients with CAP 
In critical ill patients the two main contributing factors for the frequently observed anaemia are 
inflammation and ion deficient erythropoiesis68;69• During inflammation hepcidin synthesis is 
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induced by cytokines especially by IL-670• Hepcidin is a small amino-peptide with a, recently 
discovered, important role in the iron metabolism (Figure 5 ) 71 •• A protective mechanism, including 
withdrawal of iron from the blood circulation as an essential growth factor of micro-organisms, is 
hypothesized to prevent pathogens from invading organs while increasing the efficacy of cell 
mediated immunity72•74• In addition sequestration of iron restricts its availability for haemoglobin 
synthesis. The role of hepcidin induced by inflammation, the co-existing of iron deficient 
erythropoiesis and the correlation of anaemia and clinical outcome offers potential new intervention 
strategies in patients with CAP. 
Figure 5 .  
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Hepcidin is a 25-amino acid peptide hormone that is the central regulator of body iron 
metabolism. It is synthesized in the liver (d) and secreted in plasma and binds to the cellular 
iron export channel ferroportin causing its internalization and degradation, thereby decreasing 
iron efflux from iron exporting enterocytes (a) and macrophages (c) into plasma . Increased 
iron stores and inflammation induce hepcidin synthesis, whereas suppression occurs during 
hypoxia, anaemia and increased and/ or ineffective erythropoiesis in the bone marrow (b) .  
Furthermore, hepcidin deficiency plays a central role in the iron loading in hereditary 
hemochromatosis and thalassemia's. Finally, hepcidin is induced under conditions of infection, 
decreasing the available host iron pool that is essential for survival of invading pathogens. 
Reproduced with permission75 • 
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O U T L I N E  O F  T H I S  T H E S I S  
We have studied several aspects of the host response in CAP. The focus is on monitoring and 
immunomodulation in patients with CAP. 
The role of COPD as a risk factor for patients with COPD is not clear. In Chapter 1 the relationship 
between COPD and CAP is investigated in a group of patients hospitalised with CAP. The influence 
of the commonly used severity scores Pneumonia Severity Index (PSI) and the CURB-6 s score in 
patients with CAP are explored. Furthermore, the association between concomitant corticosteroid 
use and outcome in this patient group is evaluated. 
The role of corticosteroids in the treatment of hospitalised patients with CAP is further evaluated 
in a prospective randomised clinical trial described in Chapter 2. We hypothesize that steroids 
improve clinical outcome in this patient group. 
In Chapter 3 the influence of adjunctive corticosteroids next to antibiotics on the expression of the 
frequently used biomarkers CRP and PCT is evaluated in hospitalised patients with CAP along 
with white blood cell count (WBC). We study a possible correlation between clinical outcome and 
rate of decline of CRP, PCT and WBC. 
The prognostic value of D-dimer as a biomarker in patients with CAP is investigated in Chapter 4. 
Admission D-dimer levels alone or combined with the CURB-65 score were evaluated for their 
possible role as predictor of clinical outcome in patients with CAP by means of receiver operator 
characteristics and by reclassification analysis. 
In Chapter 5 of this thesis we study the pathophysiology of anaemia as is seen in patients with CAP. 
Further investigations in the pathophysiology of CAP-related anaemia are described in Chapter 6. 
We study the potential ofhepcidin in CAP-related anaemia 
In Chapter 7 a general discussion of the studies presented in this thesis is provided and in Chapter 8 
we give some future perspectives to further expand our work on host response of CAP. 
21 
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A B ST R ACT 
Background: 
Chronic obstructive lung disease (COPD) is a frequent co-morbidity in patients hospitalised with 
community-acquired pneumonia (CAP). In recent retrospective studies, higher mortality in 
patients with CAP and COPD was found. 
Objectives: 
The aim of the study was to determine the 30-day mortality and to evaluate the differences in CAP 
severity scoring in hospitalised patients with COPD. 
Methods: 
A subanalysis of a randomized clinical trial was performed. 
Results: 
A total of 262 patients with CAP were included. Ninety-five (36.3%) patients had COPD. A total of 
28 (10.7%) patients died within 30 days. No differences between patients with and without COPD 
in 30-day mortality were observed (8 (8-4%) vs. 20 (12.0%), p = 0.37). In the Pneumonia Severity 
Index (PSI), significant differences in age, gender and heart rate between patients with and without 
COPD were observed. Patients with COPD were stratified in higher PSI classes. In the CURB-65 
score, age 6 65 years was significantly higher in patients with COPD (72 (75.8%) vs. 88 (52.7%), p 
< 0.01). In a multivariate analysis, only the need for intensive care unit admission and high serum 
glucose were predictors of mortality (OR 32.50 (95% CI 6.87-153.75), p < 0.01; OR 7.34 (95% CI 
1.19-45.4), p = 0.03). 
Conclusions: 
Mortality was not increased in patients with COPD hospitalised with CAP. Severity scores are 
influenced by age and gender. Further studies evaluating CAP in patients with COPD are needed 
to explain these findings. 
I N T R O D U CT I O N  
Community-acquired pneumonia (CAP) is a common disease associated with high morbidity and 
mortality1;2• Chronic obstructive pulmonary disease (COPD) is a frequent co-morbidity in patients 
with CAP and increases the risk of hospitalisation 2-fold3• Exacerbation of COPD is often reason for 
admission in patients with CAP and a low Pneumonia Severity Index (PSI) class4• While certain co­
morbidities such as malignancies or diabetes mellitus are associated with a higher risk of mortality, no 
significant increase in mortality was found in patients with pulmonary co-morbidity5 • In the PSI, a 
prognostic scoring model for severity of CAP, COPD is not a factor associated with a higher risk of 
mortality, although it was grouped together with asthma and interstitial lung disease6• In an 
observational study in Spain, patients with COPD had a mortality rate of 8% when admitted with 
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CAP7 • In contrast, Restrepo et al.8 found an increased mortality in hospitalized patients with COPD 
and CAP. Another study found an increase in mortality in patients with COPD admitted to the 
intensive care unit (ICU) with severe CAP9• However, some limitations were present in these studies: 
retrospective design and not using objective criteria to establish the diagnosis of COPD. Also, no clear 
information about the use of corticosteroids was given. The use of corticosteroids may be beneficial in 
patients with CAP, although this finding is not conclusive10;1 1 • In our opinion, definite conclusions 
concerning the relationship between mortality and the presence of COPD in patients with CAP are 
hard to make due to the limitations mentioned above. Patients with COPD in general have more co­
morbidities and symptoms compared to patients without COPD12• These factors can contribute to a 
higher severity class according to the PSI and a higher risk of mortality. Whether patients with COPD 
also have a more severe pneumonia according to CURB-65 is not known 1 3• The aim of the present 
study was to determine the 30-day mortality in patients admitted with CAP and COPD, as defined by 
the GOLD criteria. Furthermore, we evaluated the differences in severity scoring according to the PSI 
and CURB-65 in patients with CAP with and without COPD admitted to hospital. 
PATI ENTS AN D METHODS 
Patients 
Data were collected from a randomised clinical trial of pathogen-directed antibiotic therapy versus 
empirical antibiotic therapy in patients admitted with CAP 14• The study was conducted at the Medical 
Centre, Alkmaar, The Netherlands, a 900-bed teaching hospital. The study protocol was approved by 
the local medical ethical commission. Patients who fulfilled the following criteria were enrolled after 
informed consent was obtained: age 18 years or above; clinical presentation of an acute illness with 
1 or more of the following symptoms suggesting CAP: fever ( > 38 °C), dyspnoea, cough{with or 
without expectoration of sputum) or pleuritic chest pain; presence of new consolidations on chest 
X-ray. Patients were excluded if 1 of the following criteria were present: severe immune suppression 
(HIV infection, high dose of immunosuppressive agents, chemotherapy); malignancy; pregnancy or 
lactation; allergy to antibiotics; pneumonia within 8 days after hospital discharge. 
Microbiology 
Sputum specimen was collected at admission for Gram's stain, culture and latex antigen test for 
Streptococcus pneumoniae. The presence of 2:: 25 polymorphonuclear leucocytes and � 10 
squamous epithelial cells per low power field of a Gram-stained specimen was defined as 
'representative' sputum. Three sets of blood cultures were drawn prior to start of antibiotic therapy 
and an urine sample for S. pneumoniae and Legionella pneumophila serotype antigen testing (EIA, 
Binax-NOW; Binax, Portland, Me., USA) was obtained. Thoracentesis with Gram's stain, latex 
agglutination antigen testing for S. pneumoniae and culture was performed when pleural fluid was 
present. Paired serum samples were taken within 2 weeks for serology (Serion ELISA classic; 
Virion GmbH, Wiirzburg, Germany) for the detection of Mycoplasma pneumoniae, Chlamydophila 
pneumoniae, L. pneumophila serogroup 1-7, influenza A and B virus, parainfluenza virus 1-3, 
respiratory syncytial virus, and adenovirus. 
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Lung Function Assessment 
Patients underwent spirometric evaluation (Erich Jaeger GmbH, Wiirzburg, Germany) during 
follow-up on day 30 or day 90. Pulmonary function tests (PFT) performed before admission were 
retrieved when available. COPD was defined and categorised according to the GOLD criteria1 5 • 
Airflow obstruction was defined as a post-bronchodilator ratio of percentage predicted forced 
expiratory volume in 1 s to forced vital capacity as a percentage of predicted (FEV 1 /FVC) :::; 0.7. 
GOLD stage 1 was defined as a FEV 1 predicted� 80%, GOLD stage 2 as FEV 1 predicted between 
50 and 80%, GOLD stage 3 as FEV 1 predicted between 30 and 50% and GOLD stage 4 as FEV 1 
predicted :::; 30%. Patients with no PFT were defined as not having COPD. 
Severity Scoring 
Severity of CAP at admission was defined according to the PSI and CURB-65. The PSI score is 
composed according to a 20-point model based on clinical signs and symptom, laboratory and 
radiological findings and co-morbidity6. Patients are classified in severity classes I-V with 
increasing risk of mortality from 0.1 % in class I to 27% in class V. The CURB-65 model is composed 
by giving 1 point to each of following clinical signs of symptoms if present: confusion, urea > 7 
mmol/1, respiratory rate� 30 breaths/min, systolic blood pressure < 90 mm Hg or age� 65 years13 • 
Mortality ranges from 1.5% for a score of 0-1 point to 22% for a score of 3 or more points. 
Therapy 
Antibiotic treatment was given according to randomisation assignment and presumed aetiology as 
described in detail elsewhere14• Prescription of other medication such as corticosteroids or 
inhalation therapy was left to the discretion of the attending physician. No predefined criteria for 
total duration of antibiotics or discharge was given to the attending physician. A switch from 
intravenous to oral antibiotics was performed if patients were afebrile for 3 days. 
Statistics 
x2 tests were used for categorical variables and the Student's t test for continuous variables and 
Mann-Whitney U test for ordinal variables for calculating differences between 2 groups. The 
Kolmogorov-Smirnov test was used for assessment of normality. p < 0.05 was considered to be 
significant. A binary logistic regression was performed with 30-day mortality as the dependent 
factor. Only variables with a significant (p < 0.05) by univariate analysis were entered in the logistic 
regression. Data were analysed using SPSS version 14.5 for Windows (SPSS, Chicago, Ill., USA). 
R E S U LTS  
Study Group 
A total of 262 patients were included with a mean ( ± SD) age of 64.3 ± 18.0 years, of which 140 
(53-4%) were male. In 174 (66.4%) patients, 1 or more co-morbidities were present. The most 
frequent reported co-morbidities were obstructive lung disease (119 patients, 45.4%), diabetes 
mellitus (26 patients, 9.9%), prior history of stroke (23 patients, 8.8%), chronic heart failure (21 
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Figure 1. Flow chart of COPD assessment by means of PFT. 
262 patients 
49 patients no PFT during fol low-up  due to 
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6 (12.2%} patients 
identified with COPD by 
means of previous PFT 
43 (87.8%} patients 
designated as 
without COPD 
95 (36.3%} patients 
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89 (41.8%} 
patients with 
COPD by PFT 
124 (58.2%} patients 
with no obstructive 
PFT 
167 (63.7%} patients 
without COPD 
20 (12.0%} deaths 147 {88.0%} survivors 
patients, 8.0%) and ischemic heart disease (17 patients, 6.5%). Mean length of stay (LOS) was 13.3 
days (range 2-96). PFT were available in 213 patients (81.3%). In 49 (18.7%) patients, no data were 
obtained due to death, lost to follow-up or technical problems. In 220 (84.0%) patients, data 
concerning concomitant use of corticosteroids were available. A total of 95 (36.3%) patients had 
COPD according to the GOLD criteria (figure 1). Mean FEV 1 ± SD in the patients with COPD 
was 1.52 ± 0.77 litres with a predicted FEV 1 ± SD of 54.3 ± 20.3% and a mean FEV 1 /FVC ± SD 
of 50.5 ± 13.6. The stratification of patients with COPD in GOLD stages was as follows: 11 (11.6%) 
patients stage 1, 34 (35.8%) patients stage 2, 36 (37.9%) patients stage 3, 8 patients stage 4 (8.4%) 
and 6 (6.3%) patients had no recent lung function tests due to death during follow-up. These 
patients were diagnosed as having COPD based on PFT prior to inclusion in the study. 
Characteristics for patients with or without COPD are shown in table 1. COPD was diagnosed as 
co-morbidity by history, chart review or by PFT in 95 (36.3%) patients before admittance for the 
episode of CAP (figure 1). In 66 (25.2%) patients, this diagnosis was supported by PFT during 
follow-up. In 29 (11.1%) patients with COPD mentioned in their history, PFT during follow-up 
were not compatible with COPD as defined by the GOLD criteria. In 29 (11.1 %) other patients, 
COPD was diagnosed after hospital discharge by PFT. � -Lactam antibiotics were given in 85 
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Table 1. Demographic features of patients with and without COPD 
COPD (n=95) Non-COPD (n=1 67) p-va lue 
Age, years 70.4±10.7 60.8±20.2 <0.01 
Male 61 (66} 77 (46} 0.02 
Current smokers 33 (34.7} 41 (24.6) NS 
Pack years Pack years 32.7±20.4 28.4±19 .1 NS 
Congestive heart failure 9 (9 .5) 12 {7 .2) NS 
Diabetes mellitus 13 (13 .8) 13 (7.8} NS 
Cardiopulmonary 
morbidity other than 73 (76 .8) 49 (29 .3) <0.01 
COPD 
Inhaled corticosteroids 45 (46.9) 17 {10.) <0.01 
Figures in parentheses are percentages. NS = Not significant 
(50.9%) patients without COPD and in 45 (47.4%) patients with COPD (p = 0.61). A combination 
of� -lactam and macrolide antibiotics were prescribed in 71  (42.5%) and 43 (45.3%), respectively 
(p = 0.70). Monotherapy with a macrolide antibiotic was given in 1 1  (6.6%) patients without COPD 
and in 7 (7.4%) patients with COPD (p = 0.80). 
Mortality and Clinical Outcome 
A total of 28 (10.7%) patients died during follow-up. There were no significant differences in 
mortality between patients with or without COPD (table 2). All 8 (8.4%) deaths in the COPD group 
occurred in patients in PSI class IV or V, while 16 (8.0%) patients without COPD who died were 
stratified in class IV or V. No significant differences in 30-day mortality were observed in patients 
with and without COPD with respect to the CURB-65 score. Patients with COPD and PSI class IV 
or V had no significantly longer LOS compared to patients without COPD (14.3 ± 13.2 vs. 17.9 ± 
14.7 days ± SD, p = 0.34). Patients with COPD in PSI classes I, II and III did have a longer LOS (1 1.2 
± 3.5 vs. 10.6 ± 9.3 days ± SD, p = 0.03). No differences in LOS were observed between patients with 
and without COPD when stratified for non-severe CAP (CURB-65 score 0-2) and severe CAP 
(CURB-65 score 3-5). Sixteen (9.6%) patients without COPD and 6 (6.3%) patients with COPD 
were admitted to the ICU (p = 0.36). ICU 30-day mortality was 68.2%. There was no difference in 
ICU 30-day mortality between patients with COPD and without COPD (3/6 patients (50.0%) vs. 
12/16 patients (75.0%), p = 0.27). In table 3, data are shown for the logistic regression analysis with 
30-day mortality as outcome. The only factors associated with a higher 30-day mortality rate in the 
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Table 2. Outcome for patients with and without COPD 
COPD (n = 95) Non-CO PD (n= 1 67) p- va l ue  
30 days mortal ity (%} 8 (8.4} 20 (12.0} 0.37 
LOS ±SD (days) 12.8±10.0 13.5±12.3 0.07 
Total antibiotic duration 
9.7±3 .1  10.7±6.2 0.81 (days) 
Tota l  duration of iv 
0.86 antibiotics (days 
Systemic steroids (%} 73 (76.8} 45(26.9} < 0.01 
Data are presented as mean±SD or n(o/o). LOS: length of stay; IV: intravenous 
Table 3. Factors associated with 30 day mortality by logistic regression. 
OR (95 % Cl) p-va lue  
ICU admittance 32.50 (6 .87-153 .75} <0.01 
ICS use 0.11 (0 . 1-1. 10} 0.06 
GNB 4.19 (0 .91-19.34} 0 .07 
Glucose � 14.0 mmol/1 at 
7 .34 (1. 19-45.4} 0.03 
admission 
ICU: Intensive Care Unit, ICS : Inhaled Corticosteroids, GNB : Gram negative bacteria. 
multivariate analysis were glucose �14.0 mmol/1 at admission (p = 0.03) and the need for ICU 
admittance (p < 0.01). Inhaled corticosteroids (ICS) use showed a trend towards a protective effect, 
although it did not reach significance (p = 0.06). COPD as a co-morbidity or the use of systemic 
steroids were not entered in this model, as these factors did not contribute to a higher 30-day 
mortality in univariate analysis (p = 0.37 and p = 0.87, respectively). In table 3, data are shown for 
the logistic regression analysis with 30-day mortality as outcome. The only factors associated with a 
higher 30-day mortality rate in the multivariate analysis were glucose �14.0 mmol/1 at admission (p 
= 0.03) and the need for ICU admittance (p < 0.01). Inhaled corticosteroids (ICS) use showed a 
trend towards a protective effect, although it did not reach significance (p = 0.06). COPD as a co­
morbidity or the use of systemic steroids were not entered in this model, as these factors did not 
contribute to a higher 30-day mortality in univariate analysis (p = 0.37 and p = 0.87, respectively). 
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Severity Scoring 
Patients with COPD were more often stratified in the higher PSI classes than patients without 
COPD (figure 2). The differences in PSI classes between patients with and without COPD are 
mainly determined by differences in age and gender (table 4). The only other significantly different 
variable between the 2 groups was heart rate at admittance. No differences in CURB-65 score were 
observed (figure 3). Age 2:'.65 years was the only significant different variable (p < 0.01) when 
analysing the variables separately (table 5). 
Figure 2. Pneumonia Severity Index in patients with and without COPD. 
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Aetiology 
In 158 (60.3%) patients, an aetiological diagnosis was found. A mixed infection was found in 19 
patients. The most common isolated pathogen was S. pneumoniae in 94 (62%) cases, followed by 
M. pneumoniae (23 patients, 8.8%), H. influenzae (18 patients, 6.9%), Legionella spp. (13 patients, 
5%) and M. catarrhalis (7 patients, 2.7%). Gram-negative bacteria were identified in 14 (14.7%) 
patients with COPD and in 21 (12.6%) patients without COPD (p = 0.62). No differences in 
incidence of other pathogens were observed between both groups. In 5 of the 8 deaths in the 
COPD group an aetiological agent was found: S. pneumoniae in 1 patient, Klebsiella pneumoniae in 
1, Escherichia coli in 2 and H. influenzae in 1 patient. 
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Table 4. Differences in Pneumonia Severity Index scoring between patients with and without COPD. 
COPD (n = 95) Non-COPD (n = 167) p-va lue 
Age 70.4 (10.7) 60,8 (20.2) <0.01 
Male sex 61 (66} 77 (46) 0 .02 
Nursing home resident o (o) 5 (3 .0%} 0.09 
Liver d isease 0 (0) 3 (1.8} 0.19 
Chronic heart fa i lu re 9 (5.4} 12 (7 .2} 0 .51 
Renal d isease 1 (1. 1) 3 (1. 8} 0 .64 
Mal ignancy 3 (3 .2} 4 (2.4} 0.71 
Cerebrovasculair d isease 5 (5 .3} 18 (10 .8} 0.13 
Heart rate >125 beats per 
20 (21 .1) 17 (10 .2} 0.02 
minute 
Respiratory rate >30 
36 (37 .9} 63 (37 .7} ,� 0 .98 breaths per minute 
Body temperature < 35 °c 
8 (8,4) 14 (8.4} 0 .99 
or > 40 °c 
Systol ic b lood pressure < 
5 (5 . 3} 0(0) 0 .62 
90 mmHg 
Altered mental state 21 (22. 1) 46 (27 .5} 0 .33 
pH < 7,35 10(10.5} 9 (5.4) 0.75 
Ht < 0,30 6 (6. 3) 9 (5.4) 0 .12 
Sodium < 130 mmol/1 4(4.2} 7 (4.2) 0.99 
Glucose > 13,9 mmol/1 6 (6.3) 7 (4.2) 0 .45 
BUN >10,9 mmol/1 15 (15. 8) 37 (22 .2) 0 .21 
pO2 < 60 mmHg so (52.6%) 70 (41.9%) 0 .94 
Pleura l  effusion 5 (5 .3%} 15 (9 .0  %) 0.28 
Data is  presented as mean(SD) or as n(%). Ht: hematocrit, BUN: blood urea nitrogen, p02: partial oxygen pressure. 
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Table 5. Differences in CURB-65 scoring between patients with and without COPD. 
Confusion 
BUN > 7 mmol/1 
Respiratory rate > 30 
breaths per minute 
Blood pressure systolic > 
90 mmHg 
Age � 65 years 
COPD (n = 95) Non -CO PD (n = 167) p-value 
21 (22. 1) 46 (27.5) 0.33 
41 {43 .2) 0.71 
36 {37 .9) 63 (37.7) 0.98 
5 (5 .3) 0 (0) 0 .62 
72 (75 .8) 88 (52.7) <0.01 
Data is presented as n(%) .  BUN: Blood urea nitrogen. 
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D I S C U S S I O N  
In this study, patients with COPD did not have a higher mortality when compared to patients 
without COPD. Our finding of equal mortality is in concordance with earlier findings in the PORT 
study, but in contrast to the findings in other studies5 ;8;9• The patient group with COPD in the present 
study was well defined by using PFT, a feature lacking in the previously mentioned studies. The 
diagnosis of COPD was confirmed during follow-up in 66 patients and rejected in 29 patients. A 
new diagnosis of COPD was established in 29 patients by PFT during follow-up. Almost one third 
of the patients with presumed COPD did not have COPD, while almost one fifth of the patients 
without COPD had undiagnosed COPD as proven by PFT during follow-up. The misdiagnosis of 
COPD illustrates the bias which can be introduced by a retrospective study design. 
The relation between CAP, COPD and mortality is an intriguing one. Patients with COPD who are 
hospitalised with CAP are most likely to be older male patients. These factors contribute to a higher 
PSI score. However, a higher PSI classification in patients with COPD did not result in a higher 
mortality overall in our study. Furthermore, no differences in mortality were found with respect to 
the CURB-6 5 score between the 2 groups. However, a tendency was observed towards a lower 
incidence of early treatment failure in patients with COPD. In the study by Menendez et al. 16, COPD 
was an independent factor associated with a lower risk of treatment failure in patients with CAP. 
We found a high prevalence of COPD in the patients included in this study. This correlates with 
other studies in which COPD as co-morbidity is reported in 35-50% of hospitalised patients with 
CAP17;18• COPD is a risk factor for hospitalisation and the risk increases with declining FEV 1 19 • Also 
in the TORCH study an increase of CAP was seen in patients treated with ICS compared to patients 
receiving placebo20• Although the beneficial effects of ICS on mortality of COPD are still 
controversial, the GOLD guidelines advise ICS therapy for patients with COPD and an FEV 1 below 
50% 15 • Severity of COPD and the use of ICS contribute to the risk of hospitalisation for an episode 
of CAP. No beneficial effects of ICS on mortality were observed in this study, although there was a 
trend towards a protective effect of ICS on mortality (OR o.11, 95% CI 0.1-1.10, p = 0.06). A possible 
explanation for this observation can be the attenuation of inflammation by ICS. Whether COPD 
severity also contributes to CAP mortality will require larger prospective studies. 
More than 75% of patients with COPD were treated with systemic corticosteroids in this study. 
Also, nearly 28% of patients without COPD were treated with systemic steroids. Adjunctive therapy 
with corticosteroids can cause an attenuation of the inflammation and may improve outcome. No 
apparent effect of systemic steroids on mortality was observed in our study. In a meta-analysis of 
glucocorticosteroid therapy in patients with severe sepsis or septic shock, a reduction in mortality 
was seen in patients treated with a low-dose corticosteroid therapy for more than 5 days2 1 • In some 
earlier studies no effect was found of adding corticosteroids to antibiotics in patients with CAP. 
Marik et al. 22 found no differences in outcome in patients with severe CAP when treated with a 
single dose of hydrocortisone versus placebo before antibiotic treatment. Another study evaluating 
antibiotic therapy in patients with CAP also treated a subgroup of 20 patients with prednisolone23 • 
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No significant differences were observed between the different treatment groups. In contrast, 
Confalonieri et al.10 showed that patients with severe CAP treated with low-dose hydrocortisone for 
7 days had improved outcomes, although the study was terminated earlier because of the beneficial 
effects in the interim analysis. One possible explanation for the finding is the occurrence of adrenal 
insufficiency. Adrenal insufficiency is found in up to 60% of patients with severe sepsis or shock24:2s. 
The administration of systemic steroids in patient with severe CAP may help to restore the pituitary­
adrenal axis. There are no data regarding adrenal insufficiency in patients with non-severe CAP, but 
it is unlikely that adrenal insufficiency has a large influence in this group of patients. 
Severity scoring in CAP is useful for determining the best site of care for patients26 • The exclusion 
of disease-specific parameters for COPD in the PSI (such as exacerbation of COPD or hypercapnia) 
or the CURB-65 score (such as hypoxemia) can lead to a higher hospitalisation rate for patients 
with COPD in comparison to patients without COPD. Furthermore, when patients with COPD 
are hospitalised, in part of these parameters, it can lead to a lower severity scoring in comparison 
to patients without COPD. However, in this study patients with COPD had a higher PSI class or an 
equal CURB-65 score compared to patients without COPD. Age is one of the most important 
factors in the calculation of the PSI. The higher PSI classification in patients with COPD is likely to 
be derived from the higher age and higher percentage of males. The only clinical variable found 
significantly different between patients with and without COPD was heart rate at admission. In the 
CURB-65 score, only age �65 years was significantly higher in patients with COPD. The other 
variables did not differ between the groups. One conclusion which can be drawn from this is that 
the clinical presentation of patients with COPD and CAP do not differ from other patients with 
CAP except in age, gender and heart rate. From these findings one can suggest that severity scoring 
using the PSI or the CURB-65 can be used regardless of the presence of COPD as co-morbidity. 
Another finding is that patients with COPD did not have a longer hospital stay. One reason can be 
the long hospital stay in both groups in this study. Discharge criteria were not pre-defined and 
discharge was left to the attending physician. The finding of same LOS suggests that patients with 
CAP and COPD do not have a different reconvalescence period than patients with CAP and 
without COPD. The same applies to therapy duration, but as all these factors were not controlled 
in this study, further studies using predefined criteria for duration of therapy and discharge are 
needed for confirmation. 
Some limitations apply to this study. First, the study protocol was designed for evaluating different 
antibiotic treatment regimes, not for evaluating 30-day mortality of patients with COPD. However, 
the fact that patients regardless of co-morbidity, except being immunocompromised, were included 
is one resembling daily practice. Furthermore, the prevalence rate of COPD in our population is 
around the same percentage as in other studies, suggesting our population is again one representative 
of daily practice. Second, the mortality rate of 10.7% in this patient population is a realistic figure, 
but the absolute number can be too low for an accurate conclusion about the 30-day mortality. A 
third limitation is the diagnosis of COPD. Almost a third of the patients with COPD were diagnosed 
after discharge. Performing PFT in patients with a recent pneumonia can cause a lower FEV 1 by 
means of a persistent inflammation. We cannot exclude this potentially confounding effect, but as 
patients performed PFT on outpatients visits on days 30 and 90, we think this effect will in most 
cases be circumvented. Also, the distinction between COPD and asthma can be difficult from PFT 
only. Some patients may in fact have a form of asthma with a fixed obstruction instead of COPD. 
In conclusion, severity scoring of CAP can be used in patients with COPD. Furthermore, when 
hospitalised with CAP, patients with COPD have the same mortality rate, aetiology and demographic 
features, except for age and gender, as patients without COPD. The role of systemic corticosteroids 
in patients with COPD may contribute to this effect. In general, the role of corticosteroids in 
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A B ST RACT  
Rationale: 
Some studies have shown a beneficial effect of corticosteroids in patients with community-acquired 
pneumonia (CAP), possibly by diminishing local and systemic anti-inflammatory host response. 
Objectives: 
To assess the efficacy of adjunctive prednisolone treatment in patients hospitalized with CAP. 
Methods: 
Hospitalized patients, clinically and radiologically diagnosed with CAP using standard clinical and 
radiological criteria, were randomized to receive 40 mg prednisolone for 7 days or placebo, along 
with antibiotics. Primary outcome was clinical cure at Day 7. Secondary outcomes were clinical 
cure at Day 30, length of stay, time to clinical stability, defervescence, and C-reactive protein. 
Disease severity was scored using CURB-65 (a severity index for community-acquired pneumonia 
evaluating Confusion, blood Urea nitrogen, Respiratory rate, Blood pressure, and age 65 or older) 
and Pneumonia Severity Index. 
Measurements and Main Resu lts: 
We enrolled 213 patients. Fifty-four (25.4%) patients had a CURB-65 score greater than 2, and 93 
(43.7%) patients were in Pneumonia Severity Index class IV-V. Clinical cure at Days 7 and 30 was 
84/104 (80.8%) and 69/104 (66.3%) in the prednisolone group and 93/109 (85.3%) and 84/109 
(77.1%) in the placebo group (P = 0.38 and P = 0.08). Patients on prednisolone had faster 
defeveresence and faster decline in serum C-reactive protein levels compared with placebo. Sub 
analysis of patients with severe pneumonia did not show differences in clinical outcome. Late 
failure (>72 h after admittance) was more common in the prednisolone group (20 patients, 19.2%) 
than in the placebo group (10 patients, 6-4%; P = 0.04). Adverse events were few and not different 
between the two groups. 
Conclusions: 
Prednisolone (at 40 mg) once daily for a week does not improve outcome in hospitalized patients 
with CAP. A benefit in more severely ill patients cannot be excluded. Because of its association with 
increased late failure and lack of efficacy prednisolone should not be recommended as routine 
adjunctive treatment in CAP. Clinical trial registered with www.clinicaltrials.gov (NCT 00170196). 
I N T RO D U CT I O N  
Community-acquired pneumonia ( CAP) is a leading cause of morbidity and mortality worldwide1 • 
Despite the developments in antibiotic therapy, no substantial progress has been made in the last 
decades2 • Additional therapeutic interventions along with antibiotics may help to improve outcome 
in patients with CAP. 
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Corticosteroids have been evaluated in the past decades for treatment of sepsis and septic shock. 
Earlier studies before 1990 showed no impact on mortality, whereas studies using current 
definitions of sepsis and septic shock showed survival benefit when corticosteroids were 
administered at a low dose for a prolonged period of time3 • In contrast, the Corticosteroid Therapy 
of Septic Shock study failed to show mortality reduction in patients with sepsis4 • Only faster 
reversal of shock was observed. 
Corticosteroids in CAP might be effective in reducing excess systemic and pulmonary inflammation, 
which might translate to improved outcome5;6• One earlier study found a beneficial effect of 
hydrocortisone on the clinical course in patients with pneumococcal pneumonia7, but a more 
recent study 8 showed a marked improvement in Pa0/FI02 and also a survival advantage in patients 
with severe CAP admitted to the intensive care unit (ICU) when treated with corticosteroids. The 
study was ended after inclusion of 46 patients because of the benefit found in the interim analysis. 
This beneficial effect of steroids on severe CAP was also found in a retrospective study9. 
Our hypothesis was that adjunctive treatment with corticosteroids along with antibiotic treatment 
may improve outcome in patients with CAP. We conducted a clinical randomized placebo­
controlled trial in hospitalized patients with CAP. Primary end point was clinical outcome at Day 
7. Secondary end points were clinical outcome at Day 30, length of stay (LOS), time to clinical 
stability (TTCS), 30-day mortality, defervescence, and serum C-reactive protein levels (CRP). 
METHODS 
Patients 
Patients were prospectively enrolled between August 2005 and July 2008 at the Medical Centre 
Alkmaar, a 900-bed teaching hospital in the Netherlands. The study protocol was approved by the 
local medical ethics committee. 
Patients were eligible if they met the following criteria: (1) Written informed consent obtained. (2) 
Clinical symptoms suggestive of CAP: cough (with or without sputum), fever (>38.5°C), pleuritic 
chest pain, or dyspnea. (3) New consolidations on chest radiograph. (4) Age 18 years or older. 
Patients were excluded from the study if one of the following criteria applied: Presence of severe 
immunosuppression (HIV infection, use of immunosuppressants), malignancy, pregnancy or 
breastfeeding, use of macrolides for more than 24 hours, use of prednisone 15 mg or more for 
more than 24 hours, any condition requiring corticosteroids, any likely infection other than CAP, 
obstruction pneumonia (e.g., from lung cancer), pneumonia that developed within 8 days after 
hospital discharge, and indications that patients were unable and/or unlikely to comprehend and/ 
or follow the protocol. Subgroup analysis of patients with severe CAP (CURB-65 [severity index 
for community-acquired pneumonia evaluating Confusion, blood Urea nitrogen, Respiratory rate, 
Blood pressure, and age 65 or older] score > 2 or PSI class IV and V) was planned 10;1 1• 
Study Design 
Patients were double-blinded randomized to receive 40 mg of prednisolone once daily or placebo for 
a total of 7 days, administered in the same way as the antibiotics (intravenous or oral). When patients 
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were switched from intravenous to oral antibiotics the study drug was also switched. Randomization 
was based on a one-on-one allocation by means of prenumbered containers containing seven vials 
for intravenous administrations and seven capsules. The allocation sequence was computer 
generated and was kept in a safe at the hospital pharmacy throughout the course of the study. 
All patients were treated with antibiotics according to national guidelines12• In all patients urinary 
antigen testing for Legionella pneumophila was performed. In general, patients with mild to 
moderate severe CAP (CURB-65 < 3 or PSI I-III) were treated with amoxicillin. Patients with 
moderate to severe CAP, with (a suspicion of) atypical pathogens or with an intolerance to 
amoxicillin were started on moxifloxacin. Alteration of antibiotic treatment was allowed but the 
use of macrolides was discouraged because of their immunomodulating effect. Duration of 
antibiotic treatment was entirely left to the discretion of the medical team in charge, as was the 
decision whether or not to switch from intravenous to oral treatment. There were no criteria for 
hospital discharge and the investigators did not influence decisions concerning discharge. 
Laboratory Assessment 
Standard laboratory assessment was performed on presentation and included renal and liver 
functions, electrolytes, glucose, hematology, and CRP (Beckman Coulter Inc., Fullerton, CA). 
Arterial blood gas analysis was performed as clinically indicated. Serum samples were drawn each 
day of hospitalization until Day 7 and on Day 14 for assessment of CRP levels. 
Outcomes 
Clinical outcome at Day 7 and Day 30 was defined as: Cure-resolution or improvement of symptoms 
and clinical signs related to pneumonia without the need for additional or alternative therapy. 
Failure-persistence or progression of all signs and symptoms that developed during the acute disease 
episode after randomization, or the development of a new pulmonary or extrapulmonary infection, or 
the deterioration of chest radiography after randomization, or death due to pneumonia, or the inability 
to complete the study owing to adverse events. Indeterminate-patients receiving less than Bo% of the 
study drug for reasons other than clinical failure, a concomitant infection outside the respiratory tract 
requiring antibiotic treatment, loss to follow-up, or death unrelated to the primary diagnosis13 • 
An early failure was defined as lack of resolution of signs and symptoms of pneumonia within 72 
hours of treatment and persistence or progression thereafter. A late failure was defined as a recurrence 
of signs and symptoms of pneumonia after 72 hours of admission after an initially beneficial response 
to treatment. 
Time to clinical stability was assessed by using the criteria defined by Halm and colleagues14• In short, 
patients were clinically stable if all four of the following criteria were met: improvement of cough and 
shortness of breath, temperature less than 37.8°C for at least 8 hours, white blood cell count 
normalizing, and adequate oral intake and gastrointestinal absorption. Because of the possibility of 
elevated WBC by prednisolone use, the criterion of normalizing WBC was replaced by declining 
serum CRP levels. Defeveresence was defined as a temperature less than 37.5°C. 
Microbiological I nvestigations 
At admission, a sputum specimen was ordered for Gram stain, semiquantitative culture, and 
Streptococcus pneumoniae antigen. If possible, two sets of blood cultures were drawn before the 
start of antibiotic therapy. Urine was collected for antigen testing for S. pneumoniae and 
L. pneumophila serogroup 1 (enzyme immunoassay, Binax-NOW; Binax, Portland, ME). Pleural 
fluid if present was examined by Gram stain, culture, and S. pneumoniae antigen test. 
Blood samples for serology (Serion ELISA classic; Virion GmbH, Wiirzburg, Germany) were 
obtained on Day 1 and Day 14 of the study for detection of antibodies to Mycoplasma pneumoniae, 
Chlamydophila pneumoniae, L. pneumophila serogroup 1-7, influenza A and B virus, parainfluenza 
virus 1-3, respiratory syncytial virus, and adenovirus. A fourfold increase in antibody titer was 
considered as diagnostic. 
Statistical Analysis 
A sample size was calculated based on published data of an earlier trial in which 75 patients out of 
a total of 220 patients with CAP received steroid treatment along with antibiotic treatment1 5 • 
Clinical success was 93.3% in patients with steroids and 75.9% in patients without steroids. We 
calculated that 92 patients were needed in both arms to detect a difference of 15% between steroid 
and placebo treatment at Day 7 with a power of 80% and an a level of 0.05. 
The data were summarized as frequencies or percentages for categorical variables and as means 
and standard deviations for continuous variables. Differences between the treatment groups were 
compared by the chi-square or Fisher exact test for categorical variables and a two-sample t test or 
Mann-Whitney test for continuous variables. The Kaplan-Meier method was used to analyze time 
from admission to discharge and TTCS. Differences in LOS and TTCS between treatment groups 
were compared by a log-rank test. Hazard and odds ratios are reported with 95% confidence 
intervals. Statistical Package for Social Sciences (SPSS) version 16.0 was used for data management 
and statistical analysis. A planned interim analysis after 125 included patients with regard to 
mortality, LOS, and clinical outcome at Days 7 and 30 showed no significant differences and the 
study was continued as planned. 
RES U LTS 
Baseline Characteristics 
A total of 213 patients were enrolled in the study. Mean age was 63.5 ± 18.2 years and 124 (57.9%) 
patients were male. Study flow chart is shown in Figure 1. There was an imbalance between the two 
study groups with respect to CRP levels on admission and prevalence of chronic heart disease (Table 
1). Patients with severe pneumonia were evenly distributed among the two groups (CURB-65 score 
:2:: 3: 28 [13.1 %] vs. 26 [12.2%] patients; p = 0.61; PSI IV-V: 48 [46.2%] vs. 45 [41.3%] patients; 
p = 0-47). Reasons for exclusion are listed in Table. 
Antibiotic Treatment 
Antimicrobial treatment was similar in both study arms (Table 2). Twenty-six (25 .0%) patients in 
the prednisolone group and 25 (22.0%) patients in the placebo group were using antibiotics before 
admission (Table fa). 
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Table 1. Demographic features of the intention to treat group of hospitalized patients with CAP (213 patients). 









Chronic heart disease 
lschemic heart disease 
Clinical signs and 
symptoms 
Temperature -° C 
Systolic blood pressure 
-mmHg 
Heart rate - bpm 
Respiratory rate - /min 
C-reactive protein - mg/I 




63.0 ± 17.9 
55 (52 .9) 
28 (26. 9) 
27 (26 .0) 
19 (18 .4) 
8 (7 .9) 
10 (9 .6) 
7 (6 .8) 
10 (9 .7) 
14 (13 .6%) 
38 .3 ± 1.2 
127.8 ± 24.1 
100.6 ± 20.6 
26.5 ± 7.4 
258.5 ± 154.0 
14.8 ± 6 .8 
15 (14.4) 
I I 
Placebo group (n=109) 
64.0 ± 18.7 
69 (63 .3) 
38 (34.9) 
22 (20.2) 
24 (22 .0) 
10 (9 .5) 
12 (11.0) 
11 (10.1) 
24 (22 .2) 
22 (20 .2) 
38.5 ± 1 .0 
129.3 ± 24.5 
97.0 ± 18.7 
25.5 ± 7.2 
214.5 ± 144.2 



































33 (31 .7) 
25 (24.0) 
18 (17.3) 





35 (33 . 7) 
13 (12.5) 
26 (23 .9) 0 .24 
25 (22.9) 0 .15 
32 (29.4) 0 .38  
0 .74 
9 (8 .3) 0 .92 
0 
12 (11.0) 0 .35 
21  (19.3) 0 .73 
31 (28.4) 0 .05 
28 (25 .7) 0 .20 
17 (15.6) 0 .52 
Data are presented as  n (%)  or  mean ± SD. COPD: chronic obstructive pulmonary disease; WBC: white blood cell count; 
ICU: intensive care unit. 
Table 2. Antimicrobial treatment in the two study groups 
Prednisolone group Placebo group p-value 
Amoxicillin 58 (55 .8) 64 (58 .7) 0.66 
Moxifloxacin 42 (40.4) 38 (34.9) 0.41 
Amoxicillin/clavulanic 
4 (3 . 8) 5 (4.6) 0.79 
acid 
Amoxicillin and acyclovir 0 1 (0.9) 
Ciprofloxacin and 
0 1 (0.9) 
cefuroxime 
Data are presented as n(%). 
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Figure 1. Study flow chart 
301 Subjects were screened 
88 were excluded 
- 18 Refused to participate 
- 70 Did not meet eligibility critearia 
213 subjects underwent randomisation 
l 
104 subjects were assigned to 
prednisolone 
l 
Post randomisation exclusion, n=7 
2 withdrew consent 
1 pulmonary embolism 
1 malignancy 
1 M. Wegener 
2 did not receive study medication 
l 
97 subjects for per protocol analysis 
Clinical Outcome 
l 
109 subjects were assigned to receive 
placebo 
l 
Post randomisation exclusion, n=7 
3 withdrew consent 
2 haematological malignancies 
1 malignancy 
1 M. Churg-Strauss 
l 
102 subjects for per protocol analysis 
Primary and secondary outcome parameters are shown in Table 3. No differences in clinical 
outcome at Day 7 were found between patients in the prednisolone and placebo groups (80.8% vs. 
85.3%; p = 0.38). Kaplan-Meier plots of LOS and TTCS are shown in Figures 2 and 3. A total of 37 
( 17 .4 % ) patients did not complete their course of study medication. Reasons for not completing the 
course of study medication were: death in 10 patients, overruling decisions by attending physician 
to prescribe corticosteroids in 14 patients (3 patients with COPD and 1 patient with asthma), 
withdrawal of informed consent in 5 patients, and postrandomization exclusion in 8 patients. 
There were no differences between the prednisolone group and the placebo group in the need for 
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Length of stay {days) 
Log rank, 0.84; hazard ratio, 1 . 15 ;  95% confidence interval, 0.81-1. 5 5 ;  p = 0.36. 
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51 









20 20 20 40 
Data are presented as mean ± SD. * p < 0.0 1 .  
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Data are presented as mean ± SD. * p = 0.0 3 ;  cp p < 0.01.  
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-<>- Predn isolone 
Placebo 
Table 3. Clinical outcome by intention-to-treat and per protocol analysis. 
Outcome I 
Intention to treat 
Clinica l  cure at day 7 
Clinical cure at day 30 
30 day mortal ity 
LOS - days 
TTCS - days 
Early fa i lure 
Late fa i lure 
Per protocol 
Clinical cure at day 7 
Clinical cure at day 30 
30 day morta l ity 
LOS - days 
TTCS - days 
Early fa i lure 





6/104 (5 .8) 
10.0 ± 12.0 






10.0 ± 12.1 
5 .0 ± 7.0 
13/97 {13 .4) 
18/97 (18 .6) 
Placebo group 
93/109 {85 .3) 
84/109 (77 . 1) 
6/109 (5 .5) 
10.6 ± 12.8 
4.9 ± 5.2 
14/109 (12 .8) 
10/109 (9 . 2) 
87 /102 {85.3) 
79/102 {77 .5) 
6/102 {5. 9) 
10.4 ± 13 . 1  
4 . 9  ± 5.3 
13/102 {12.7) 















Odds ratio or mean 
difference (95% Cl) 
0.72 (0. 35-1.49) 
0.59 (0 .32-1.07) 
1.05 (0. 33-3 .37) 
-0 .56 (-4.00-2.8) 
0.03 (-1.6-1. 7 1) 
1.06 {0 .48-2.33) 
2 .36 (1.05-5. 3 1) 
0 .76 (0 .36-1.60) 
0.59 (0 .36-1. 11) 
1.06 (0 .33-3 . 39) 
-0.40 {-4.01-3 .22) 
0 .12 (-1. 68-1.92) 
1.06 (0.47-2.42) 
2.35 (1.00-5.53) 
All data are presented as n (%) or mean±sd. LOS: length of stay; TTCS: time to clinical stability. 
additional corticosteroids (six [5.8%] vs. 8 [7.3%] patients; p = 0.64). Of the 14 patients who were 
given additional corticosteroids, 7 (50.0%) were admitted to the ICU. Resolution of fever was faster 
in the prednisolone group (Figure 4). Median (±interquartile range [IQR]) day of defervescence 
was Day 2 ± 1 day in the prednisolone group and Day 3 ± 2 days in the placebo group (p < 0.01). 
The decline in CRP levels was faster in the prednisolone group up until Day 7 (Figure 5). At Day 
14, patients in the prednisolone group had higher CRP levels compared with patients in the placebo 
group (41 .73 ± 64.98 vs. 22.05 ± 53.32 mg/L; p < 0.01). 
In patients with nonsevere CAP late failures occurred more often in the prednisolone group than 
in the placebo group (CURB-65 0-2; 15/76 vs. 5/87 patients; P < 0.01 and PSI classes 1-111; 10/56 
vs. 4/64 patients; p = 0.05). 
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In the prednisolone group, five (4.8%) patients with late failure needed an additional course of 
antibiotics, seven (6.7%) patients needed another or a prolonged course of prednisolone, and six 
(5.8%) patients developed a pleural effusion or empyema necessitating additional therapy. In the 
placebo group, two (1.8%) patients needed additional antibiotics, three (2.8%) patients needed a 
course of prednisolone, and one patient developed a pleural effusion requiring additional therapy. 
Sub analysis of primary and secondary outcome parameters in patients with severe CAP ( CURB-
65 > 2 or PSI class 4-5) are shown in table 4. Subanalysis of mechanically ventilated patients 
showed no differences in the primary and secondary outcome parameters (Table E3). 
Table 4. Sub analysis of clinical outcome of severe pneumonia as defined by CURB-65 score > 
2 or PSI class > 3 by intention to treat analysis. 
CURB-65 3-5 
Cl in ical cure at day 7 
Clin ical cure at day 30 
30 day morta l ity 
LOS - days 
TTCS -days 
Early fa i lure 
Late fai lure 
Pneumonia severity 
index classe 4-5 
Cl i n ical cure at day 7 
Cl in ical cure at day 30 
30 day mortality 
LOS - days 
TTCS -days 
Ea rly fa i lure 






19.4 ± 20.2 






15.0 ± 16.4 
13/48 (27 .1) 
10/48 (20.8) 
Placebo group 
15/26 (57. 7) 0.76 
10/26 (38 .5) 0.55 
3/45 (11.5) 0.76 
20.4 ± 22.7 0.87 
8.7 ± 9 . 8  
10/26 (38.5) 0.84 
5/26 (19 .2) 0.30 
32/45 (71 .1) 0.50 
26/45 (57.8) 0.45 
5/45 (11 .1) 0 .91 
16.4 ± 18 .4 0.71 
6 .8 ± 7.6 
12/45 (26 .7) 0.96 
6/45 (13 .3) 0.34 
Odds ratio or mean 
d ifference (95% Cl) 
0.85 (0 .29-2.48) 
1.39 (0 .47-4 .10) 
1.28 (0.26 - 6.35) 
-1.00 (-13.24-11.24) 
1.13 (-5 .18-7.43) 
0.89 (0.94-2.69) 
0.91 (0.23-3.61) 
0 .74 (0.31 - 1.77) 
0.73 (0 .32 - 1 .66) 
0.93 (0.25 - 3 .46) 
-1 .38 (-8 .85 - 6.09) 
1.96 (-3 .07 - 4.71 
1.02 (0 .41 - 2.56) 
1.71 (0.57 - 5.17) 
All data are presented as n (%) or mean±sd. LOS: length of stay; TTCS: time to clinical stability. 
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Table 5. Sub analysis of mechanical ventilated patients 
A total of 21 (9.9%) patients needed mechanical ventilated. 
Clinical outcome parameters in patients on mechanical ventilation 
Clinical cure at day 7 
Clinical cure at day 30 
LOS - days 










5 {33 .3%) 
10 {66.6%) 
1 {6.7%) 
Data are presented as mean(percentage) or median (IQR) 
Cause 
Placebo group (n=6) 
3 {50.0%) 
2 {33 .3%) 
25 {12-51.3) 












An etiological diagnosis for CAP was made in 1 18 ( 5 5 .4%) patients; S. pneumoniae (78 [ 36.6%] ) 
was the most frequently found causative microorganism. Distribution of the pathogens between 
the two groups is shown in Table 5. Patients with pneumococcal pneumonia in the prednisolone 
group had a lower clinical cure rate than patients with pneumococcal pneumonia in the placebo 
group. The clinical cure rate in the prednisolone group at Day 7 and Day 30 was 29 (69.0%) and 20 
(47.6%). In the placebo group the clinical cure rate was 3 1 (86.1 %) and 28 (77.8%) (p = 0 .08 and 
p = 0.01) .  Patients with pneumococcal pneumonia and prednisolone treatment also had a 
significantly higher number of late failures ( 1 1  [26.2%] vs. 2 [ 5 .6%] ; p = 0.02). Patients in the 
prednisolone group who had no pathogen identified had a shorter TTCS than patients in the 
placebo group (3 [IQR, 2] vs. 4 [ IQR, 2] days; p= o.oi), a shorter LOS ( 5 . 5  [IQR, 3] vs. 7 [ IQR 7]  
days; p= 0.03), and faster defervescence (2  [IQR, 1 ]  vs. 3 [IQR, 3 ]  days; p < o.o1). No other 
differences were observed with respect to etiology and clinical outcome. 
Adverse Events 
Hyperglycemia with the need for additional therapy during admission occurred in five (2.3%) 
patients in the prednisolone group and two (0.9%) patients in the placebo group (p = 0.27) .  
Confusion during admission was noted in four ( 1 .9%) patients in the prednisolone group and in 
three ( 1 .4%) patients in the placebo group (p= 0.72). A superinfection occurred in 10  (2.1 %) 
patients in the prednisolone group and in 4 ( 1 .9%) patients in the placebo group (P = 0. 1 0) .  One 
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Table 6. Aetiology of 2 1 3  patients with CAP. 
Prednisolone group (n=104) Placebo group (n=109) 
S. pneumoniae 42 (40.4) 36 (33 .0) 
M. pneumonlae 7 {6.7)* 7 (6 .4) 
L. pneumophila 1 (LO) 7 (6.4) 
Gram negative bacteria 4 (3 . 8) 4 (3 .7} 
Staphylococcus aureus 2 (L9} 0 
Streptococcus lntermedius 0 1 (LO) 
I nfluenza A/B 5 § 1 (LO) 
Adenovirus 2 (L9) 1 (1.0) §§ 
No pathogen 45 (43 .3} so (45.9} 
Data are presented as n (%). *Mixed infection with S.pneumoniae 
§ 1 Mixed infection Influenza A/H. injluenzae, 2 mixed infection Influenza A/S. pneumoniae 
§§1 mixed infection M. pnewnoniae!S. pneumoniae 
patient in the placebo group developed a fungal infection after he was treated with hydrocortisone 
for septic shock in the ICU after clinical failure. Another patient in the placebo group was diagnosed 
with pulmonary embolism 10 days after hospital admission. A total of 63 (60.6%) patients in the 
prednisolone group and 72 (66.1%) in the placebo group did not have any treatment-related 
adverse event (p = 0-41). 
D I S C U S S I O N  
This is the first randomized double-blinded placebo-controlled trial of corticosteroids in hospitalized 
patients with CAP. We found no beneficial effects of adjunctive corticosteroids in patients hospitalized 
with CAP; clinical cure was equal in both groups at Day 7. A trend toward a higher clinical cure rate 
in the placebo group was observed. The overall clinical cure rate (83% at Day 7 and 71.8% at Day 30) 
is in concordance with other studies 16• Our findings contrast with the findings in other recent studies. 
In experimental studies a benefit has been found with the combination of hydrocortisone and 
antibiotics17;18• Both studies demonstrated a reduction in inflammatory cytokines. The use of 
ciprofloxacin and hydrocortisone in a piglet model of Pseudomonas pneumonia also decreased 
bacterial burden more than ciprofloxacin-treated or untreated piglets. In the only randomized double-
blinded clinical trial published to date, evaluating corticosteroids in patients with CAP admitted to 
the ICU, a marked reduction in mortality and LOS was found 19• The study included a small number 
of patients because the study was ended after interim analysis showed reduced mortality and improved 
oxygenation in patients treated with corticosteroids. A Spanish retrospective study also found a 
reduced mortality in patients treated with corticosteroids20• Both these studies only included patients 
with severe CAP, who are more likely to benefit from corticosteroids. A possible rationale for the use 
of corticosteroids is the existence of relative adrenal insufficiency in severe CAP21 • However, patients 
included in the Corticosteroid Therapy of Septic Shock study had sepsis or septic shock, with one­
third of the patients suffering from a pulmonary infection 22• There were no better outcomes in patients 
who were non responders to a corticotrophin test. In our study, subanalysis of patients with severe 
CAP did not show a beneficial effect of corticosteroids, although our definition of severe CAP was 
based on the CURB-65 or the PSI, not the modified American Thoracic Society criteria as used by 
Confalonieri and colleagues 2P4. Also, the absolute numbers of patients who needed mechanical 
ventilation was low. Gotoh and colleagues25 examined adrenal insufficiency in 64 patients hospitalized 
with CAP and found a low incidence of adrenal insufficiency in this population. Only 14  % fulfilled 
the criteria for adrenal insufficiency. Adrenal insufficiency is probably not clinically relevant in 
patients with non-severe CAP. 
Symptom resolution, reduction of LOS, and reduction of intravenous antibiotic therapy are also 
important clinical goals in the treatment of patients with CAP. In a study by Mikami and colleagues26 
the authors concluded that corticosteroids in patients with CAP hastens symptom resolution and 
shortens the duration of treatment with intravenous antibiotics. No effect on LOS was observed, but 
this study had a low number of included patients and the open-label design. The anti-inflammatory 
effects of prednisolone did not lead to a shorter LOS or TTCS in our study, despite the observed faster 
defeveresence and decline in CRP in patients treated with prednisolone. The more than twofold 
increase of late failures in the prednisolone group raises questions about the occurrence of a rebound 
of inflammation after initial suppression by corticosteroids. Subclinical inflammation is found in a 
majority of patients with severe CAP. In a large study elevated IL-6 levels were found in clinically 
stable patients with severe CAP on the day of discharge. Furthermore, higher IL-6 levels were 
correlated with a higher mortality in the subsequent 3 months27 • The assumption of rebound of 
inflammation in our study is strengthened by the higher CRP levels in patients in the prednisolone 
group after 2 weeks, after an initially faster decline in the first week. This rebound phenomenon is also 
observed in the study by Garcia-Vidal and colleagues28 • Nonsurvivors on corticosteroid therapy died 
later than nonsurvivors without corticosteroids (13.8 vs. 7.1 d, respectively). The effect of a delayed 
inflammatory response due to withdrawal of corticosteroids can cause a prolongation of the time 
between admission and death in the nonsurvivors with corticosteroids. In light of the presence of 
subclinical inflammation in patients with CAP on hospital discharge, a tapering of corticosteroids 
might protect patients against the rebound of inflammation29• Another possible explanation for the 
higher incidence of late failure may be nosocomial infection, leading to additional treatment. 
Nevertheless, similar to this trial, a recent metaanalysis found no evidence of increased risk for 
nosocomial infections in corticosteroid-treated patients30• In our study, the inclusion of patients with 
nonsevere pneumonia may have resulted in a higher rate of late failures instead of increased late 
mortality. Late failures may lead to new or prolonged courses of antibiotics or corticosteroids and 
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subsequently to a higher risk of adverse events. The corticosteroid treatment-related adverse events in 
our study, however, were low and did not differ from placebo. The time to clinical stability was similar 
between the two groups, with a mean of 5 days. As the TTCS can be used as a decision tool for safely 
switching antibiotics from intravenous to oral administration, the effect of prednisolone on the 
duration of intravenous antibiotic therapy will be limited 31 • CAP can be caused by different pathogens 
and the effect of prednisolone on the different pathogens can also be different. Patients with 
pneumococcal pneumonia treated with corticosteroids had a higher clinical failure rate in our study. 
No effects on outcome with respect to other pathogens were noted, although the absolute numbers in 
our study may have been be too small to detect such differences. 
Some limitations may apply to our study. First, no assessment of adrenal function was performed in 
these patients, so no data regarding the presence of relative adrenal insufficiency are known. Second, 
the use of clinical cure as primary outcome is a subjective outcome parameter, prone to bias. But in our 
opinion this reflects daily clinical practice and because of the randomized design the introduction of 
bias is minimized. 
Furthermore, the exclusion criteria of the need for corticosteroid therapy may have led to an 
underrepresentation of patients with COPD. The simultaneous occurrence of bronchial obstruction 
and CAP in patients with COPD necessitates the use of systemic corticosteroids in these patients32• 
Although the question of whether mortality by CAP is higher in patients with COPD is still a subject 
for debate, the possible exclusion of these patients may have created a selection bias (33;34_ The percentage 
of patients with COPD in our study was 20.2%, whereas in a previous study in our hospital 36.6% of 
the patients with CAP had COPD35 • Our findings should not be extended to patients with CAP and 
COPD, as generalizability is limited. 
A fourth possible limitation is that our study may have been underpowered to detect a clinically 
significant difference in this population, which also included a large proportion of nonsevere 
pneumonia. But even in this case, the number needed to treat to detect a favorable outcome with 
prednisolone will not be clinically relevant. Also the effect of prednisolone can be diminished by a late 
administration. As the clinical cure rate is rather high in nonsevere pneumonia, the administration of 
prednisolone 24 hours after admission is not likely to have a significant effect on the clinical course. As 
all patients were included within 24 hours of admission, we do not believe this limits our findings. 
The Dutch guidelines concerning antibiotic therapy in patients with CAP differ from the Infectious 
Diseases Society of America/American Thoracic Society guidelines (36m. The low antibiotic resistance 
in the Netherlands (see http://www.swab.nl/swab/cms3.nsf/nethmap2oo9-o4/$file/h4.htm) and the 
conflicting data in the literature concerning combination therapy support the antibiotics used in this 
study conducted in the Netherlands 35;39 
As the last limitation, we used prednisolone in a once-daily dosage, for practical reasons, which may 
not be sufficient for establishing effective serum levels during 24 hours, although the pharmacodynamic 
effects are known to last beyond the time frame indicated by pharmacokinetic parameters. This limits 
the comparison with studies using hydrocortisone by continuous infusion. 
In conclusion, prednisolone at 40 mg once daily for 1 week does not improve outcome in hospitalized 
patients with CAP. A benefit in more severely ill patients cannot be excluded. Because of its association 
with increased late failure in patients with nonsevere CAP and lack of benefit, prednisolone should not 
be recommended as routine adjunct treatment in CAP. 
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A B ST R A C T  
Introduction: 
There is little data on the influence of corticosteroids on biomarkers in patients with community­
acquired pneumonia (CAP). 
Objectives: 
To assess the influence of prednisolone on the levels of C-reactive protein (CRP), procalcitonin 
(PCT) and white blood cell count (WBC) in patients with CAP 
Methods: 
Serial measurements of CRP, PCT and WBC were analysed in patients in a randomised trial treated 
with antibiotics or with antibiotics and prednisolone. 
Results: 
In 1 76 patients data on CRP, PCT and WBC were available. In patients with severe CAP ( CURB-
65 �3) CRP and PCT levels were higher (260±146 mg/I versus 230±151 mg/I, p=o.25 and 
23.26±32.08 µg/1 versus 4.69±8.84 µg/1, p<o.01). Patients with clinical success had lower CRP 
levels(225±145 mg/I versus 270±160 mg/I, p=o.09) and significant lower PCT levels(6.94± 
13.08 µg/1 versus 15 .60±29.27 µg/1, p=o.01) on admission. Patients with clinical success at day 
30 had higher differences in CRP and WBC during treatment with antibiotics and prednisolone, 
but not in PCT levels. Patients with clinical failure with antibiotics and prednisolone had a 
marked decline in CRP (�day1-day3 118±148 mg/1), while patients with clinical failure with 
antibiotics alone had an increase in CRP (�day1-day3 -18±169 mg/I, p<o.0 1). Admission 
biomarkers levels, decline of biomarkers or prednisolone were not independently associated 
with clinical failure. 
Conclusion: 
CRP and WBC in patients with CAP are influenced by prednisolone, while PCT is not. In patients 
with CAP treated with corticosteroids CRP should not be used for assessing treatment response 
I N T R O D U CT I O N  
In patients with Community-Acquired Pneumonia (CAP) whom require hospitalisation, 10 to 15  % 
will not adequate respond to treatment1 • Treatment failure in these patients is related to several risk 
factors, including pneumonia risk class and adherence to antibiotic guidelines2;3• Biomarkers, 
especially C-reactive protein (CRP) and procalcitonin (PCT) may help to identify patients at risk 
for treatment failure4-6• Furthermore the use of serial PCT measurements can be used to reduce 
antibiotic treatment duration in patients with CAP7• Treatment with adjunctive corticosteroids 
occurs in a large proportion of patients with CAP8 • There is limited data on the effect of 
corticosteroids on the expression of these biomarkers9; 10• In a randomised clinical trial of adjunctive 
prednisolone therapy in patients with CAP the levels of CRP declined faster during the days of 
treatment in patients treated with prednisolone1 1 • In this secondary analysis of the above mentioned 
randomised clinical trial we investigated the influence of prednisolone on CRP, PCT and WBC 
levels during treatment in patients with CAP. We also explored the association between these 
biomarkers, prednisolone use and clinical outcome. 
M ET H O D S 
Patients 
The present study was part of a randomised clinical trial assessing the adjunctive treatment with 
corticosteroids in patients hospitalised with CAP1 1 • In short patients were treated with a 7 day 
course of 40 mg prednisolone o.d. or placebo next to guideline-adherent antibiotic treatment. 
CAP was defined as the presence of a new infiltrate on the chest radiograph along with clinical 
signs and/ or symptoms suggestive of pneumonia in a patient. Patients with immunosuppressive 
therapy, malignancies or venous thromboembolism were excluded. Patients in whom no PCT data 
was available on day 1 or 2 were also excluded from this study. 
Severity assessment 
Severity of CAP at admission was defined according to the CURB-65 score1 2• The CURB-65 model 
is composed by giving one point to each of the following clinical signs or symptoms if present: 
Confusion, Urea> 7 mmol/1, Respiratory rate 2:'. 30 breaths per minute, systolic blood pressure < 90 
mmHg and diastolic blood pressure < 60 mmHg or age 2:'. 65 years. Patients with a CURB-65 score 
of 3 or higher were classified as having a severe CAP. 
Laboratory methods 
Blood samples were drawn into Vacutainer� tubes, anticoagulated with K2EDTA (Becton 
Dickinson, Plymouth, UK) and plain tubes (Vacutainer SST, Becton Dickinson, Plymouth, UK). 
Blood samples were analyzed within 4 hours after collection. For additional investigations of 
biochemical parameters reflecting activity state of infection serum samples were stored in aliquots 
at -20 • C until analysis. 
Haemocytometric parameters, such as WBC counts were established by measurement on a Sysmex 
XE-2100 Hematology Analyzer (Sysmex Corporation, Kobe, Japan). 
Procalcitonin (PCT) concentration was established by applying Kryptor B.R.A.H.M.S. PCT 
Sensitive assay (Brahms AG, Germany) on the Kryptor Compact analyser (Brahms AG, Germany). 
Serum concentrations of CRP were established by application of a Prospec nephelometer (Dade 
Behring, Mar burg, Germany). 
Daily measurements were performed during hospital stay on day 1 to 7 and on day 14. 
In cases in which no PCT samples on day 1 were available these were substituted by PCT samples 
on day 2. Most were taken within 24 hour after starting antibiotic treatment. 
The results are the same when using paired PCT samples between day 1 and the other days or PCT 
samples between day 2 and the other day (data not shown). 
Table 1. Demographic features of the included patients (n=176) 









Diabetes mel l itus 
Neurological d isease 
Chronic heart d isease 
lschemic heart d isease 
C l in ical signs and 
symptoms 
Temperature -° C 
Systol ic  b lood pressure 
-mmHg 
Diastol ic blood 
pressure - mm Hg 
Heart rate - bpm 
Respiratory rate - /min 
66 
Al l  patients (n=176) 
63.8 ± 18.1 
105 (59 .7) 
47 (26 .7) 
37 (21 .0) 
41 (23 .3) 
17 (9.7) 
15 (8 . 5) 
20 (11.4) 
15 (8 .5) 
29 (16.5) 
30 (17.0) 
38.5 ± 1 .1  
129.2 ± 24.8 
72.0 ± 14.9  
98 .5 ± 19 .4 
26.3 ± 7 .3  
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64.7±18 .1  
28  (30 .8) 
14 (15.4) 
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Figure 1. Study flowchart 
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Figure 2. Levels of C-reactive protein (A), procalcitonin (B) and WBC (C) in patients treated with antibiotics 
and in patients treated with antibiotics and prednisolone during the first seven days of treatment and on day 14. 
Data are presented as mean with 95% CI. * p<o.01 ,  ** p=o.02, cp p=o.04. 
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Figure 3. Levels ofC-reactive protein (A), procalcitonin (B) and WBC (C) in patients with clinical succes or failure 
at day 30 during the first seven days of treatment and on day 14. Data are presented as mean with 95% CI 
::::::. 500 
bO ...... Clinical cure at day 30 


























1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Days 
69 
Figure 4. The differences between days of treatment ofC-reactive protein (A), procalcitonin (B) and WBC (C) in 
patients treated with antibiotics and patients treated with antibiotics and prednisolone with clinical success at day 30. 
Data are presented as mean with 95% CI. 
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Figure 5. The differences between days of treatment ofC-reactive protein (A), procalcitonin (B) and WBC (C) in 
patients treated with antibiotics and patients treated with antibiotics and prednisolone with clinical failure at day 30. 
Data are presented as mean with 95% CI 
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Table 2. Differences in C-reactive protein, procalcitonin and white blood cell count in patients treated with prednisolone 
and antibiotics in relation to clinical success or failure at day 30. 
Clinical success Clin ical failure p-value 
CRP - mg/1 �day 1-day 3 60 (-17 - 152) 67 (-74 - 158) 0.22 
�day 1-day s 154 (45 - 259) 185 (3 - 268) 0.53 
�day 1-day 7 143 (57 - 251) 214 (63-288) 0.73 
�day 1-day 14 192 (99-313) 148 (61-293) 0.62 
PCT- µg/1 �day 1-day 3 0.40 (0.05-2 .81) 0 .93 (0 .02-4.16) 0.92 
�day 1-day 5 0.91 (0. 16-7.09) 3 .31 (0 .24-10.5) 0.41 
�day 1-day 7 1.59 (0.21-9.24) 4.00 (0 .27-16.00) 0.36 
�day 1-day 14 1.00 (0.18-7.59) 3 .73 {0 .23-9.01) 0.39 
WBC - 109/I �day 1-day 3 2.9 {-0.1-7.2) 1.7 {-1 .8-4.0) 0 .46 
�day 1-day s 4.8 {1.0-8.8) 1 .5  (-4.8-4.6) <0.01 
�day 1-day 7 4.8 (1.2-8.7) 0 .0 (-3 .7-7.60 0.14 
�day 1-day 14 6.7 (2 .9-10.3) 4.7 (-1.1-11.4) 0.30 
Clinical outcome 
Clinical outcome at day 3 o was defined as: Clinical success-resolution or improvement of symptoms 
and clinical signs related to pneumonia without the need for additional or alternative therapy. 
Clinical failure-persistence, or progression of all signs and symptoms that developed during the 
acute disease episode after randomization or the development of a new pulmonary or extra­
pulmonary respiratory tract infection, or the deterioration of chest radiography after randomization, 
or death due to pneumonia, or the inability to complete the study owing to adverse events. 
Statistics 
Differences between groups were compared by the chi-square test or the Fisher exact test for 
categorical variables and by a two-sample T-test or Mann-Whitney test for continuous variables. 
The Kolmogorov- Smirnoff test was used for assessing normal distribution. A p-value < 0.05 was 
considered significant. Statistical Package for Social Sciences (SPSS*) version 16.0 was used for 
data management and statistical analysis. Binary logistic regression was performed for identifying 
factors contributing to clinical failure at day 30. Variables were included in this model if they had 
a p value < 0 .1  in the univariate analysis. 
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Table 3. Univariate analysis of parameters contributing to clinical success or failure at day 30 . 
Age - yrs 
Prednisolone use 
Temperature - ° Celsius 
Systolic blood pressure 
- mm Hg 
Diastolic blood pressure 
- mm Hg 
Heart rate - bpm 
Respiratory rate - min·1 
C-reactive protein - mg/I 
Procalcitonin - µg/I 
White blood cell count - 109/1 




lschemic heart disease 
Chronic heart disease 
Antibiotics prior to admission 
Bacteremic CAP 
Inhaled corticosteroid use 






No aetiological diagnosis 





















41 (31 .8%) 
11 (8 .5) 
7 (5.4) 
59 (45.4%) 
Clinical failure at day 30 
(n= 49) 
69.7±14.1 














11 (23 .9) 
12 (25 .5) 
5 (26.3) 
5 (16.7) 
24 (51 .1) 
2(4.3) 






0 . 8  
0 . 57 






0 . 72 
0 .21 
0 .31 
0 .98  







0 . 17 
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Table 4. Multivariate analysis of parameters contributing to clinical failure at day 30. 
Odd's ratio 95 % confidence interval 
Age -years 1.02 0.99-1.05 
I ntensive care un it admittance 0.23 0.04-1.25 
Temperature at admission 0.54 0.34-0.86 
CRP increase with 10 mg/I 1.01 0.98-1.05 
Proca lciton in - µg/1 1.00 0.98-1.03 
Respiratory rate - min-1 1.07 0 .99-1.15 
Pneumococcal pneumonia 1.15 0.34-10.09 
Inhaled corticosteroid use prior 
0.99 0.29-3 .30 to admittance 
Predn isolone use 0.64 0.27-1.75 
�WBC day 1-5 - 109/I 0.93 0.86-1.00 
CRP: C-reactieve protein; WBC: White blood cell count 











A total of 176 out of 213 patients were included in this study (figure 1). Patient characteristics are 
shown in table 1. A total of 1 1  (6.3%) patients died within 30 days after admission. Amoxicillin was 
prescribed as initial antibiotic to 101 (57.4%) patients, amoxicillin-clavulanic acid in 7 (4.0%), 
moxifloxacin in 67 (38.1 %) and amoxicillin-acyclovir in 1 (0.6%) patient. 
C-reactive protein 
The mean (±sd) CRP level on admission was 237±150 mg/1. Patients with severe CAP (CURB-65 
� 3) had a non-significant higher CRP level as compared to patients with non-severe CAP (CURB-
65 < 3) (260±146 mg/1 versus 230±151 mg/1, p=o.25). 
Procalcitonin 
The mean(±sd) CT level on admission was 9.12± 19.07 µg/1. Patients with severe CAP had higher 
PCT levels on admission than patients with non-severe CAP, respectively 23.26±32.08 µg/1 and 
4.69±8.84 µg/1, (p <0.01). 
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White blood cell count 
The mean WBC(±sd) on admission was 15.0*109/1±7.0*109/L Patients with severe CAP had a WBC 
on admission of 15.5*109/l ±9.0*109/l, while patients with non-severe CAP had a WBC of 14.9*109/l 
±6.3*109/1 (p=o.60) 
In figure 2 the levels of the three biomarkers in the group treated with antibiotics and in the group 
treated with antibiotics and prednisolone are shown during the first seven days of treatment and 
on day 14. 
Biomarkers, prednisolone and clinical outcome 
A total of 129 (73.3%) patients had a clinical success at day 30. These patients had a trend towards 
a lower CRP level on admission (225±145 mg/1 versus 270±160 mg/1, p=o.09), a significant lower 
PCT level on admission (6.94±13.08 µg/1 versus 15.60±29.27 µg/1, p=o.01) but not in WBC 
(15.0*109/l ±6.4*109/l versus 15.1 *109/l ±8.6*109/1, p=o.93). Seventy-two (79.1 %) patients treated 
with sole antibiotics had a clinical success at day 30 , while 57 (67.1 %) patients treated with 
antibiotics and prednisolone had a clinical success at day 30 (p=o.07 ). 
There were no significant differences in decline of CRP and PCT with respect to clinical cure or 
failure at day 30. Only the difference in WBC between day 1 and 5 was different with respect to 
clinical outcome (table 2 and figure 3). 
Patients with a clinical success at day 30 had higher differences in CRP levels and WBC between 
days of treatment when treated with antibiotics and prednisolone, but not in PCT levels (figure 4). 
In patients with a clinical failure at day 30 there were differences in decline in CRP levels (figure 5). 
Patients with clinical failure treated with antibiotics and prednisolone had a marked decline in 
CRP levels between day 1 and day 3 ( �day 1- day 3 u8±148 mg/1), while patients with a clinical 
failure treated with antibiotics alone had a slight increase in CRP levels instead (�day 1- day 3 
-18±169 mg/1, p<o.01). 
Multivariate analysis 
The results of the univariate analysis for clinical outcome at day 3 o are shown in table 3. In the 
multivariate analysis levels of biomarkers on admission, decline of biomarkers or use of prednisolone 
were not independently associated with clinical failure at day 30 (table 4). 
D I S C U SS I ON 
In the present study serum levels of CRP and WBC in hospitalised patients with CAP are influenced 
by prednisolone therapy. In contrast PCT levels are not significantly influenced by prednisolone 
therapy. The faster decline in CRP levels in patients treated with antibiotics and prednisolone 
may suggest an attenuated immune response attributable to the anti-inflammatory effects of 
prednisolone. 
The inflammatory response in patients with CAP is not completely understood. The over expression 
of pro-inflammatory cytokines may be the cause of clinical failure in these patients. However not 
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all patients with CAP have these elevated pro-inflammatory cytokines at admission and the patients 
with the highest risk of death have elevated levels of interleukin-1 o, an anti-inflammatory cytokine, 
next to high levels of pro-inflammatory cytokines13 • 
The effect of corticosteroids on CRP levels has been observed in several studies14;15 • CRP is 
synthesized in the liver under influence of interleukin 6 and interleukin-6 levels in patients with 
CAP are influenced by corticosteroids16 ;17 • Three studies have found an improved clinical outcome 
in patients with severe CAP when treated with corticosteroids18-20• These studies do have some 
methodological flaws such as premature stopping, retrospective study design and low power due 
to small numbers of patients; this may have introduced a bias. The data in the present study is 
collected from a randomized placebo controlled clinical trial in which there was no improved 
clinical outcome in patients hospitalized with CAP when treated with prednisoloneu. 
More importantly patients with a clinical failure at day 30 had a marked decline in CRP levels in 
the first five days when treated with prednisolone, while patients with a clinical failure at day 30 
without prednisolone had only a small decline in CRP levels after the first three days of treatment. 
In the multivariate analysis the levels of biomarkers or decline in levels of biomarkers were not 
independently associated with clinical failure. This demonstrates that decline in CRP levels is not 
a marker of overall treatment response in patients with CAP while on corticosteroid therapy. There 
is a paucity of data on the relationship between biomarkers, corticosteroids and clinical outcome 
in patients with CAP. Monton et al. 21 found a lower CRP levels in patients with severe CAP treated 
with corticosteroids than in patients without corticosteroids. There was no difference in CRP levels 
in survivors and non-survivors treated with corticosteroids. In contrast Perren et al.9 found no 
differences in CRP and PCT decline in patients with CAP. This study consisted of a small number 
of patients, in which patients with COPD and CAP were treated with antibiotics and corticosteroids 
and patients with CAP were treated with antibiotics alone. 
PCT is a prohormone which is increased in bacterial infection and sepsis while being not elevated 
in viral infections22• Two studies found no differences in PCT expression by corticosteroids9; 10• In 
contrast patients with secondary episode sepsis expressed a lower level of PCT than patients with 
a first episode of sepsis23 • This might be explained by the higher rate of prior corticosteroid use in 
patients with secondary sepsis. In our study the expression of PCT was not significantly influenced 
by prednisolone therapy. 
The effect of leukocytosis after prednisolone administration is a well-known effect24;25 • WBC was 
increased during the seven days in the patients treated with antibiotics and prednisolone. There 
were no differences in WBC in patients with clinical failure with respect to prednisolone use. 
Tools for monitoring and guiding treatment in patients with CAP are beneficial and much needed. 
Two studies have elegantly shown the usefulness of consecutive CRP and PCT measurements in 
patients with CAP7;14• Our study clearly demonstrates that in patients with CAP treated with 
corticosteroids consecutive CRP measurements cannot be used for assessing treatment response. 
This study has some limitations. The study was designed for assessing prednisolone therapy on the 
clinical outcome of hospitalized CAP. The inclusion of patients with incomplete biomarker data, 
mostly PCT levels on day 1 may have had an impact on the results as PCT levels on day 1 will be 
likely more elevated than levels on day 2. With the available data no substantial differences were 
observed when substituting PCT levels on day 1 with PCT levels on day 2. The use of antibiotics 
according to the Dutch guidelines is not in correspondence with the ATS/IDSA guidelines and can 
be considered discordant therapy according to the latter guidelines26• 
In conclusion CRP serum levels and WBC in patients with community-acquired pneumonia are 
influenced by prednisolone, while PCT serum levels are not. In patients with CAP treated with 
corticosteroids CRP levels should not be used for assessing treatment response. 
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A B ST R ACT 
Background: 
D-dimer levels are in several studies elevated in patients with CAP. In this study we assess the use 
of D-dimer levels and its association with severity assessment and clinical outcome in patients 
hospitalised with community-acquired pneumonia 
Methods: 
In a subset of a randomised trial patients with community-acquired pneumonia serial D-dimer 
levels were analysed. CURB-6 5 scores were calculated at admission. 
Results: 
A total of 147 patients were included. D-dimer levels at admission were higher in patients with 
severe CAP (2166±1258 versus1630±1197 µg/1, p=o.03), with clinical failure at day 30 (2228 ±1512 
versus1594±1078 µg/1, p=o.02) and with early failure (2499±1817 µg/1 versus 1669±1121  µg/1, 
p=o.01). Non-survivors had higher D-dimer levels (3025±2105 versus 1680±1128µg/l , p=o.05). 
None of the 16 patients with D-dimer levels < 500 µg/1 died. In multivariate analysis D-dimer 
levels were not associated with clinical outcome. D-dimer levels have poor accuracy for predicting 
clinical outcome at day 30 (AUC 0,62 , 95% CI 0.51-0.73) or 30 day mortality (AUC 0,71 (95% CI 
0.51-0.91). Addition of D-dimer levels to CURB-65 did not increase accuracy. No differences were 
observed in serial D-dimer levels between patients with clinical success or failure at day 30. 
Conclusion: 
D-dimer levels are elevated in patients with CAP. Significantly higher D-dimer levels are found in 
patients with clinical failure and with severe CAP. D-dimer levels as single biomarker or as addition 
to the CURB-65 have no added value for predicting clinical outcome or mortality. D-dimer levels 
< 500 µg/1 may identify candidates at low risk for complications. 
I N T R O D U CT I O N  
Community acquired pneumonia (CAP) is associated with a considerably high morbidity and 
mortality1 • Despite improvements in antimicrobial therapy, supportive therapy and prognostic 
models, mortality in CAP did not reduce in the last decades2 • Early identification of patients with 
CAP with poor clinical outcome or at risk treatment failure may be helpful in increasing the overall 
cure rate. Several severity assessment tools for patients with CAP have been developed. These 
severity scores are composed of clinical signs and symptoms, laboratory results and in case of the 
pneumonia severity index (PSI) co-morbiditiesM. Furthermore several biomarkers such as 
C-reactive protein (CRP) and Procalcitonin (PCT) have been evaluated and can successfully 
predict mortality in patients with CAP5 • 
In patients with sepsis the role of coagulation as an important factor next to the inflammatory 
component has been recognised 6. In a large proportion of patients with sepsis CAP is identified as 
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the underlying cause7• Also in a large proportion of patients with severe CAP coagulation is 
activated and some studies have demonstrated a relationship between D-dimer levels and severity 
of CAP8- 1 1 • D-dimers are fibrin degradation products which have been shown to be useful in a 
clinical decision rule for ruling out pulmonary embolism 1 2• As measurement ofD-dimer levels are 
readily available in most emergency rooms this test may help to improve severity assessment in 
patients with CAP. 
Biomarkers might also be used to evaluate the response to treatment, and to de-escalate therapy. 
PCT has been shown to be useful in reducing the duration of antibiotic therapy in patients with 
CAP13 • CRP can be used for monitoring treatment response in patients with severe CAP14• Whether 
D-dimer levels can be used as indicator of treatment response, is not known. 
In a sub group of patients with CAP included in a previously reported randomised clinical trial we 
assessed the use of consecutive D-dimer levels after admission to hospital, and explored its 
association with disease severity assessment and with clinical outcome1 5 • 
METH ODS 
Patients 
This is a secondary analysis of patients included in a randomised clinical trial assessing the added 
value of treatment with corticosteroids in patients with CAP1 5 • In short patients were treated with 
a 7 days course of 40 mg prednisolone o.d. or placebo next to antibiotic treatment. For the present 
study patients were included, irrespective of the allocation of treatment, in whom on the first day 
of admission D-dimer levels were collected. 
CAP was defined as the presence of a new infiltrate on the chest radiograph and clinical signs and/ 
or symptoms suggestive of pneumonia in a patient. Patients with immunosuppressive therapy, 
malignancies or venous thrombo-embolism were excluded. 
Severity assessment 
Severity of CAP at admission was defined according to the CURB-65 score3 • The CURB-65 model 
is composed by giving one point to each of following clinical signs of symptoms if present: 
Confusion, Urea> 7 mmol/1, Respiratory rate � 30 breaths per minute, systolic Blood pressure < 90 
mmHg and/or diastolic blood pressure ::; 60 mm Hg, or age � 65 years. Patients with a CURB-65 
score of 3 or higher were classified as having a severe CAP. 
Laboratory methods 
Routine laboratory assessments were performed on admission. 
D-dimer levels were analysed by using an ELISA-method (VIDAS& D-Dimer Exclusion"' , 
BioMerieux SA, France). Daily measurements of D-dimer levels were performed during hospital 
stay until day 7. Measurement of D-dimer levels was performed on day 14 regardless whether the 
patients was hospitalized or discharged. 
Table 1. Demographic features of included and excluded patients. 
I ncluded patients (n=147) 
Age - yrs 63.1 ± 17.8 
Male gender 79 (53.7) 
Current smoker 41 (28.5) 
Never smoker 37 (25.2) 
ICU admission 17 (11.6) 
Comorbid ities 
COPD 27 (18.4) 
Asthma 14 (9 .5) 
Diabetes mel l itus 15 (10.2) 
Neurological d isease 10 (6.8) 
Chronic heart disease 25 (17.0) 
lschemic heart disease 27 (18.4) 
Cl inical signs and symptoms 
Temperature -° C 
Systol ic blood pressure -mmHg 128.2 ± 25 .2 
Diastol ic b lood pressure - mmHg 71.9±15 .7 
Heart rate - bpm 100.7 ± 19.7 
Respiratory rate - /min 26.2 ± 7.9 
C-reactive protein - mg/I 240.3 ± 151.8 
WBC - x  109/1 14.9 ± 6.9 
D-dimer - µg/1 1753±1228 
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Excl uded patients (n=66} 
64.6±19.4 
46 (69 .7) 
21 (33.3) 
12 (18.5) 
5 (7 . 6} 
16 (24.6) 
4 (6.5) 
6 (9 .1) 
8 (12 .3) 
10 (15.6%) 




























Score 1 40 (27.2) 17 (25 .8) 
Score 2 44 29.9) 14 (21.2) 
Score 3 24 (16.3) 11 (16.7) 
Score 4 9 (6.1) 9 (13.6) 
Score 5 l (0.7) 0 
Data are represented as n (%) or mean±SD. COPD: chronic obstructive pulmonary disease; 
WBC : white blood cell count; ICU : intensive care unit. 
Clinical outcome 
Clinical outcome at day 30 was defined as: 






1 .  Clinical success-resolution or improvement of symptoms and clinical signs related to 
pneumonia without the need for additional or alternative therapy; 
2. Clinical failure-persistence, or progression of all signs and symptoms that developed during 
the acute disease episode after randomization or the development of a new pulmonary or extra­
pulmonary respiratory tract infection, or the deterioration of chest radiography after 
randomization, or death due to pneumonia, or the inability to complete the study owing to 
adverse events. 
An early failure was defined as lack of resolution of signs and symptoms of pneumonia within 72 
hours of treatment, and persistence or progression thereafter. A late failure was defined as a 
recurrence of signs and symptoms of pneumonia after 72 hours of admission following an initially 
beneficial response to treatment. 
Time to clinical stability (TTCS) was assessed by using criteria adapted from Ramirez et al. 16• In 
short patients were clinically stable if all four of the following criteria were met: improvement of 
cough and shortness of breath, temperature below 37.8°C for at least 8 hours and adequate oral 
intake and gastrointestinal absorption. The criteria of normalising white blood cells was omitted 
due to possible interaction with prednisolone therapy. 
Statistics 
Differences between groups were compared by the chi-square test for categorical variables and a 
two-sample T-test or Mann-Whitney test for continuous variables. Statistical Package for Social 
Sciences (SPSS·) version 16.0 was used for data management and statistical analysis. Binary logistic 
regression analysis was performed. Variables with a p-value < 0.1 on univariate analysis were 
entered in the multivariate analysis. Goodness of fit was assessed by the Hosmer-Lemeshow -test. 
ROC-curves for predicting clinical outcome at day 30 and mortality at day 30 were calculated. Net 
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Table 2. Mean D-dimer levels by CURB-65 stratification 
Mean±SD Mean±SD p-value 
CURB-65 score o 1306±976 Score 1 1319±626 0.61 
Score 2 2125±1531 0.02 
Score 3 1948±1196 0.04 
Score 4 2635±1377 <0.01 
CURB-65 score 1 13 19±626 Score o 1306±976 0.61 
Score 2 2125±1531 <0.01 
Score 3 1948±1196 0.05 
Score 4 2635±1377 <0.01 
CURB-65 score 2 2125±1531 Score o 1306±976 0 .02 
Score 1 1319±626 <0.01 
Score 3 1948±1196 0 .63 
Score 4 2635±1377 0.36 
CURB-65 score 3 1948±1196 Score o 1306±976 0.04 
Score 1 1319±626 0.05 
Score 2 2125±1531 0.63 
Score 4 2635±1377 0.17 
CURB-65 score 4 2635±1377 Score o 1306±976 <0.01 
Score 1 1319±626 <0.01 
Score 2 2125±1531 0.36 
Score 3 1948±1196 0.17 
Data are presented as mean±SD. 
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Figure 1. Mean D-dimer levels at admission. Figure 1A: mean D-dimer levels by stratification in the CURB-65 score. 
Figure 1B: mean serum D-dimer levels in patients with severe CAP or non severe CAP as defined by the CURB-65 .  
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Table 3. Multivariate analysis for prediction clinical failure at day 30 - 95 % confidence intervals 
Adjunctive prednisolone treatment 
CURB-65 score 
D-dimer levels per 1000 µg/1 increase 
Bacteremic pneumococcal pneumonia 
ICU admittance 
ICS 










0.52-7.13 0 .33 
0.05-1.63 0 .16 
0.05-0.92 0.04 
Figure 3A. ROC curve for predicting clinical success at day 30. The AUC for predicting clinical success at day 30 for 
D-dimer was 0,62 (95% CI 0.5 1-0.73), for CURB-65 score was 0.70 (95% CI 0.60-0 .81)  and for CURB-65 combined with 
D-dimer 0.71 (95% CI 0.60-0.81) .  
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CURB-65 score and D·dimer 
Reference Line 
Figure 3B. ROC curve for predicting 30 day mortality. The AUC for predicting 30 day mortality was 0,71 (95% CI 
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CURB-65 score and D-dimer 
Reference Line 
Figure 3C. ROC curve for predicting the need for mechanical ventilation. The AUC for predicting the need for mechanical 
ventilation for D-dimer was 0.75 (95% CI 0.63-0.87), for CURB-65 score 0.93 (95% CI 0.88-0.98) and for CURB-65 
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Table 4. Reclassification tables for predicting clinical success at day 30, 30 day mortality and need for mechanical ventilation. 
Reclassification table for predicting clinical outcome at day 30 with the CURB-65 score 
without and with serum D-dimer levels. 
High risk 1 53 
1 Patients with c l in ical fa i lu re at day 30 
Low risk 25 3 3 
High risk 0 9 
Net reclassification improvement 5 . 5% ( 95% CI;-6.2 % -17%, p=o.36) 
0 
Reclassification table for predicting 30 day mortality with the CURB-65 score without and with serum D-dimer levels. 
High risk 6 9 
High risk 0 4 
Net reclassification improvement 16.1 % ( 95% CI; -8.7%-40.9%, p=o.20) 
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Reclassification table for predicting the need for mechanical ventilation with the CURB-65 score 
without and with serum D-dimer levels. 
H igh risk 0 14 
H igh risk 0 13 
Net reclassification improvement 2.8% ( 95% CI; -9.1 %-14.7%, p=o.64) 
reclassification improvement (NRI) was calculated by the methods described by Pencina et al. 17• 
For the NRI-calculations the CURB-65 score was reclassified in two risk groups of equal size for 
each of the following outcome variables: clinical success at day 30, 30 day mortality and the need 
for mechanical ventilation. 
RES U LTS 
A total of 213 patients were included in the original study. In 66 patients no D-dimer levels were 
obtained on the first day of admission, resulting in 147 patients included for this analysis. 
Demographic features are shown in Table 1. Mean D-dimer level at admission was 175 5±1288 
µg/1. In Figure 1 the serum D-dimer level in relation to the CURB-65 score is shown. Patients with 
a severe CAP (CURB-65 score > 2) had higher D-dimer levels as compared to patients with a non 
severe CAP( 2166±1258 µg/1 versus 1630±1197 µg/1, p=o.03). In Table 2 more detailed information 
is provided. A total of 8 (5 .4%) patients died within 30 days. Mean serum D-dimer levels in non­
survivors were higher than in survivors, 3025±2105 µg/1 versus 1680±1128µg/l (p=o.05, Figure 2). 
Patients with an early treatment failure had higher D-dimer levels than patients without early 
treatment failure (2499±1817 µg/1 versus 1669±1121 µg/1, p=o.01). However in patients with late 
treatment failure no significant differences in D-dimer levels were found (2070±1310 µg/1 versus 
1704±1213 µg/1, p=o.25). 
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Figure 4. Serial measurements of D-dimer levels in patients with CAP. In figure 4A the serial D-dimer levels of all patients 
are shown. In figure 4B the serial measurements of patients with clinical success and clinical failure at day 30 are shown. 
Data are presented as mean with 95 % CI. 
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Seventeen ( 11.6%) patients were admitted to the ICU at admission or within 24 hours of admission. 
All these patients were mechanically ventilated. D-dimer levels in patients admitted to the ICU 
were higher than in patients admitted to the ward (3074±1705 µg/1 versus 1833±1161µg/l, 
p<o.01). 
In 16 patients D-dimer levels were below 500 µg/1 Three (18.8 %) of these patients had a clinical 
failure within 30 days necessitating additional treatment, but none died within 30 days Mean 
length of stay (LOS) in the study population was 10.1±12.9 days (median 7 days). Mean TTCS was 
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4.8±5.6 days (median 3 days). Patients with a LOS < 7 days had lower D-dimer levels on admission 
compared to patients with a LOS 2:: 7 days (1359±883 µg/1 versus 1963±1244 µg/1, p<o.01). Also 
patients with a TTCS < 3 days had lower D-dimer levels at admission than patients with a TTCS 2:: 
3 days (1219±816 µg/1 versus 1798±1170 µg/1, p=o.01). 
In the logistic regression model for the prediction of clinical success at day 30 the following 
variables (p-value <0. 1 in the univariate analysis) were entered: prednisolone use, CURB-65 score, 
bacteraemic pneumococcal pneumonia, inhaled corticosteroids (ICS) use and D-dimer level 
increase per 1000 µg/1. Only inhaled corticosteroid use was correlated with improved clinical 
outcome (Table 3). 
The accuracy of D-dimer at admission for prediction clinical outcome at day 30,30 day mortality 
and the need for mechanical ventilation was poor to moderate (Figures 3A-C). The addition of 
D-dimer at admission to the CURB-65 score yielded no improvement in predicting of clinical 
outcome at day 30 (AUC 0.70, 95% CI 0.60-0.81 versus 0.71, 95% CI 0.60-0.81), 30 day mortality 
(AUC 0.83, 95% CI 0.72-0.94 versus 0.84, 95% CI 0.71-0.97) or need for mechanical ventilation 
(AUC 0.93, 95% CI 0.88-0.98 versus 0.94 95% CI 0.90-0.98) The combination of CURB-65 score 
and D-dimer yielded also no improvement in reclassification of risk for clinical success at day 
30,30 day mortality or need for mechanical ventilation (Table 4). 
In Figure 4 the serial measurements of D-dimer levels during treatment is presented. Patients with 
clinical success at day 30 had a mean D-dimer level of 1594±1078 µg/1 while patients with clinical 
failure at day 30 had a mean D-dimer 2228 ±1512 µg/1 (p=o.02). 
No significant differences were observed in the serial D-dimer levels between the groups of patients 
with clinical success or failure at day 30. 
CONC L U S I ONS AN D D I S CU SS I ON 
In this analysis of a subset of patients included in a randomised clinical trial we demonstrated a 
limited value in the use of D-dimer levels in patients with CAP for assessment of severity and 
outcome. 
In the literature several studies examined D-dimer levels and compared those with severity and 
outcome in patients with CAP. All of these studies demonstrated that D-dimer levels are close 
related to severity of CAP and possibly to outcome10;1 1 ;ia;i9• These studies included mostly mild to 
moderately severe cases of CAP. In one recent study evaluating 90 ICU patients with CAP, D-dimer 
levels were also correlated with outcome and performed equally well as APACHE II and SOFA­
score20. 
In the present study there is a significant correlation between D-dimer levels and severity as 
assessed by the CURB-65 score. Clinical success was also associated with low D-dimer levels. In 
our study non survivors had a higher D-dimer level on admission although this did not reach 
statistical significance. This could be due to the low absolute mortality rate - only 8 patients died. 
The longer LOS, although not significant, and longer TTCS in patients with a high D-dimer 
suggests that D-dimer is a possible biomarker for clinical outcome in patients with CAP. 
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The search for a useful biomarker in patients with CAP is still ongoing. Previous studies with CRP 
and PCT have shown some promising results. Higher CRP levels are associated with the need for 
hospitalization, with severity and with S. pneumoniae and L. pneumophila as causative agent21 -23 • 
PCT had the same accuracy in predicting severity and outcome as the CRB-65 score, an adaption 
of the CURB-65 score24• In a Spanish study the combined use of CRP and two severity scores 
( CURB-6 5 and PSI) yielded the highest accuracy in predicting mortality5• 
In contrast in our study the clinical value of admission D-dimer levels at admission was low in 
prediction clinical success with an AUC of 0.63 for predicting clinical cure at day 30 and an AUC 
of 0.70 for predicting 30 day mortality although the confidence intervals are wide for both 
endpoints. NRI calculation also did not lead to a significant improvement of predicting clinical 
outcome by combining CURB-65 score and D-dimer levels. Admission D-dimer level did have a 
moderate AUC for predicting the need for mechanical ventilation, although is was outperformed 
by the CURB-65 score. The observed lack of sensitivity for predicting clinical outcome, mortality 
or for the need of mechanical ventilation in our study limits the use of D-dimer as a single predictive 
biomarker. Studies including more patients or higher mortality are needed to confirm this finding. 
The addition of D-dimer at admission levels to the CURB-65 score yielded no improvement. Our 
findings support the study by Chalmers et al. 25 , who demonstrated that patients with CAP with 
D-dimer levels in the reference range (e.g. < 500 µg/1) have a low risk of death and major morbidity. 
The percentage of patients in their study with a D-dimer level within the reference range was 
higher than in our study, probably reflecting the fact that our patients were all hospitalized patients 
instead of patients recruited from the Emergency Department, some of whom could be subsequently 
managed as out-patients. Nonetheless, the percentage of patients with low D-dimer levels and 
clinical failure was low in our study, supporting the hypothesis that D-dimer testing is useful as an 
adjunctive marker to identify patients with CAP who can be treated as outpatients. These 
observations warrant further evaluations. 
Furthermore in the present study serial measurements of D-dimer were not helpful in identifying 
patients with clinical improvement or deterioration as D-dimer levels were in most cases elevated 
until day 14 and even then only show a modest though significant decrease. 
This study has some limitations. At first D-dimer levels are elevated in many conditions which at 
presentation can be difficult to distinguish between CAP and other conditions such as pulmonary 
embolism. The patients we included in the present analysis were not systematically assessed for the 
presence of pulmonary embolism, but only if clinically suspected. Furthermore, the overall 
mortality was low ( 5 .4 % ) which may be too low for any useful observations regarding mortality in 
these patients. The included patients in this group were mainly patients with mild to moderately 
severe CAP. 
In conclusion D-dimer levels are elevated in patients with CAP. Significantly higher D-dimer levels 
are found in patients with clinical failure, in non-survivors and in patients with severe CAP. 
However D-dimer levels as a single biomarker or as addition to the CURB-65 score have no added 
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value for predicting clinical outcome. The only exception is that low D-dimer levels at admission 
( <500 µg/1) may identify candidates at low risk for complications that may therefore be suitable 
candidates for ambulatory treatment. Serial measurements of D-dimer are not useful in monitoring 
patients or in guiding therapy changes as the changes over time are minimal in patients with 
clinical success and in patients with clinical failure. 
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Introduction: 
In case of inflammation, imbalance of iron homeostasis is caused by increased retention of iron 
within cells of the reticuloendothelial system. Iron restricted erythropoiesis occurs because of 
decreased availability of iron for haemoglobin (Hb) synthesis in erythroid progenitor cells. 
Objectives: 
Deviations in reticulocyte haemoglobin content (Ret-He) are investigated together with 
inflammation markers in subjects with community- acquired pneumonia (CAP). Short-term 
alterations with regard to Ret-He during and after completing antibiotic treatment are 
investigated. 
Methods: 
A total of 75 patients, classified in three subgroups with CURB-65 scores of �1, 2 and �3, 
participated in the study. 
Results: 
Within the three subgroups Hb results demonstrate a decline from the day of admission until day 
4. From day 4 an increase towards higher values is observed at day 14. Within 24 hours after 
admission Ret-He results are situated within the lower quartile region of the reference range 
interval. Until day 4 of hospital admission a steady trend towards a decline of 3-8% is established. 
During antibiotic treatment an increase of reticulocyte count occurs from 0.039±0.014 1012/1 at 
day 4 to 0.057±0.020 1012/1 at day 14 (mean ± SD). Recovery of Hb and Ret-He occurs towards 
values within the reference range. 
Conclusions: 
In subjects with CAP, acute inflammation results in impairment of RET-He at an early stage. After 
onset of pneumonia decreased results of Ret-He and Ret He/RBC-He ratio are demonstrated, 
reflecting acute erythropoietic dysfunction which are amongst others due to functional iron 
depletion. 
I N T R O D U C T I O N  
The condition indicated as the anaemia of inflammation refers to subjects with acute or chronic 
immune activation. A protective mechanism including retention of iron from the blood circulation 
as an essential growth factor, preventing pathogens from invading organs while increasing the 
efficacy of cell mediated immunity1• Cytokines and cells of the reticuloendothelial system are able 
to induce changes in pathophysiology concerning iron homeostasis. Phenomena reflecting the 
pathophysiology of anaemia are decreased proliferation of erythropoietic progenitor cells, 
reduction of erythropoietin stimulation and a shorter life span of red blood cells (RBCs)2• 
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In healthy subjects, reticulocyte maturation occurs with progressive reduction in RBC size and 
haemoglobin content (RBC-He). Haemoglobin content of reticulocytes (RET-He) yields actual 
information concerning the functional availability of iron for haemoglobinization in erythroid 
precursors3 
In case of inflammation, imbalance of iron homeostasis is due to increased retention of iron within 
cells of the reticuloendothelial system. As a result, iron restricted erythropoiesis occurs because of 
decreased availability of iron for Hb-synthesis in erythroid progenitor cells4 The amount of studies 
concerning the impact of infection on erythropoiesis is limited5 • 
Innovation of haematology analysers yields procedures for classification of RBCs and reticulocytes. 
In case of subjects with an anaemia of inflammation, results of Ret-He and Ret-He/RBC-He ratio 
combined with conventional parameters like mean cell volume (MCV), haemoglobin (Hb) and 
mean cell haemoglobin concentration (MCHC) should be considered in order to achieve an 
appropriate clinical interpretation with regard to deviations in Hb synthesis. 
With the application of a longitudinal study design deviations of Ret-He are investigated combined 
with simultaneous monitoring of inflammatory markers in subjects with community- acquired 
pneumonia (CAP). The aim of the study is to look for short-term alterations with regard to Ret-He 
during and after completing antibiotic treatment. 
S U BJ ECTS AN D M ETHODS 
Study design 
The study protocol was approved by the local medical ethics committee of the Medical Centre 
Alkmaar. 
Seventy-five patients (male n=48, female n=27) with a medical history and clinical and radiological 
findings consistent with CAP requiring hospitalisation were enrolled in the study. Inclusion criteria 
were, written informed consent, age 2:'. 18 years, new consolidation(s) on the chest radiograph and 
clinical presentation of acute illness with one or more of the following symptoms indicating CAP: 
temperature (2:'. 38°C), dyspnoea, cough (with or without expectoration of sputum), chest pain. 
Exclusion criteria: pregnancy or lactation, severe immunosuppression, neoplastic disease, any 
condition requiring corticosteroid treatment prior to admission for pneumonia (as in case of 
COPD, asthma), pneumonia which developed within 8 days after hospital discharge, obstruction 
pneumonia (e.g. due to lung cancer). At hospital admission severity of illness was scored with 
application of the CURB-65 score. CURB-65 score is a severity index for CAP classification 
evaluating degree of confusion, blood urea nitrogen, respiratory rate, blood pressure and age 65 or 
older6 • The group of patients was subdivided in three groups with CURB-65 scores �1  (n=38), 2 
(n=21), and 2:'.3 (n=16) respectively. 
Patients received antibiotic treatment for seven days according to locally used guidelines7 • Subjects 
were monitored daily with regard to clinical stability. Time to clinical stability was scored according 
to the criteria from Halm et al8.aboratory investigations were performed at hospital admission and 
subsequently once a day until day 7. The final measurement was performed on day 149• 
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Table 1. Evaluation ofhaemocytometric parameters, including mean value, standard deviation (SD), minimum-maximum 
values are established in 75 subjects with CURB-65 scores $;1, 2 and 2::3. The longitudinal study concerns results at hospital 
admission (day 1), during antibiotic treatment (day 4) and after antibiotic treatment (day 14). 
RBC (1012/L) �1  
2 
�3 
Hb (g/L) �1 
2 
�3 
MCV {fl) �1  
2 
�3 






(min - max) 
4.48 ± 0.50 
(2 .91 - 5.40} 
4.29 ± 0.48 
(2.91 - 4.87) 
4.09 ± 0.52 
(3 .26 - 5.18} 
137 ± 13 
(105 - 163) 
129 ± 14 
(89 - 153) 
127 ± 18 
{100 - 171) 
89.6 ± 5 .0 
(78 .1 - 101.4) 
90.0 ± 3 .7 
(83 .8  - 98.3) 
92.0 ± 5 .1  
(83 .5  - 103 .9) 
341 ± 13 
(317 - 372) 
336 ± 11 
{317 - 356) 
341 ± 11 
(319 - 357) 
4 .21 ± 0.40 4.48 ± 0.47 
(3 .52 - 5 .18} (3 .55 - 5 .42} 
3 . 89 ± 0 .46 4.17 ± 0.25 
(2.47 - 4.53) (3 .80 - 4.70) 
3 .76 ± 0 .39 3 .86 ± 0 .41 
(3 . 13 - 4.38) (3 .12 - 4.54) 
127 ± 11 137 ± 13 
(106 - 156) (108 - 164) 
118 ± 14 126 ± 10 
(76 - 135) (113 - 143) 
116 ± 13 
121 ± 13 
(95 - 137) 
(95 - 134) 
89 .6  ± 4 .6 90.6 ± 5 .2  
(78 .2 - 98 .3) (79 .2  - 104.2) 
90 .6 ± 3 .8  91 .5 ± 3 .8  
(84.0 - 99 .2) (85 . 1 - 99 .5) 
91 .2 ± 6 .1  
93 .1  ± 5 .9 
(82.0 - 102.9) 
(84.8 - 103. 5) 
340 ± 11  336 ± 10 
(319 - 362) (319 - 357) 
332 ± 10 328 ± 10 
(314 - 348) (314 - 345) 
336 ± 10 330 ± 8 
(324 - 356) (322 - 348) 
Figure 1.Results (Mean ± SD) for reticulocytes count (10 12/L, A) and immature reticulocyte fraction (IRF, 1012/L, B) which 
have been established in 75 subjects with CURB-65 scores $1 (=1),  2 (= 2) and :?:3 (= 3) at hospital admission (day 1) ,  at 
several days during antibiotic treatment (day 2, 3, 4, 5 and 7) and after antibiotic treatment (day 14). The horizontal lines 
indicate the lower and upper level of the reference range for apparently healthy subjects. 







1 2 3 4 5 6 14 1 2 3 4 5 6 14 1 2 3 4 5 6 14 







1 2 3 4 5 6 14 1 2 3 4 5 6 14 1 2 3 4 5 6 14 
103 
Figure 2.Results (Mean ± SD) for reticulocyte haemoglobin content (RET-He, pg, A) and red blood cell haemoglobin 
content (RBC-He, pg, B) which have been established in 75 subjects with CURB-65 scores :S:1 (=1), 2 (= 2) and �3 (= 3) at 
hospital admission (day 1), at several days during antibiotic treatment (day 2, 3, 4, s and 7) and after antibiotic treatment 
(day 14) .  The horizontal lines indicate the lower and upper level of the reference range for apparently healthy subjects. 
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Figure 3.Results (Mean ± SD) for concentrations of procalcitonin (µg/L) which have been established in 75 subjects with 
CURB-65 scores S1 (=1), 2 (= 2) and �3 (= 3) at hospital admission (day 1), at several days during antibiotic treatment 
(day 2, 3, 4, 5 and 7) and after antibiotic treatment (day 14). The horizontal line indicates the upper level of the reference 
range for apparently healthy subjects. 
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Preparation of blood samples 
Blood samples were drawn into Vacutainer� tubes, anticoagulated with K
2
EDTA (Becton Dickinson, 
Plymouth, UK) and plain tubes (Vacutainer SST, Becton Dickinson, Plymouth, UK). Blood samples 
were analyzed within 4 hours after collection. For additional investigations of biochemical 
parameters reflecting activity state of infection serum samples were stored in aliquots at -20 • C 
until analysis. 
Haemocytometry 
Haemocytometric parameters were established by measurement on a SysmexXE-2100 Haematology 
Analyzer (Sysmex Corporation, Kobe, Japan). Reticulocyte methodology of measurement is based 
on automated fluorescent flowcytometry utilizing a polymethine dye for binding cytoplasmic 
RNA. The mean forward light scatter intensity in the reticulocyte channel is estimated as a measure 
reflecting the particle volume and Hb content of RBCs and reticulocytes respectively. Results 
concerning Hb content are initially reported as RBC-Y for RBCs and RET-Y for reticulocytes. 
Subsequently, algorithms y=6.4*e0·0009*Ret-Y and y= 6-4*eo.o009•RBC-Y are applied to transform 
arbitrarily reported channel numbers of the RET-Y and RBC-Y into haemoglobin content 
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equivalents. Hb content in reticulocytes and RBCs is expressed in pg and denoted as RET-He and 
RBC-He respectively. 
Parameters reflecting inflammatory state of infectious disease 
Procalcitonin (PCT) concentration was established by applying Kryptor B.R.A.H.M.S. PCT 
Sensitive assay (Brahms AG, Germany) on the Kryptor Compact analyser (Brahms AG, 
Germany). 
Statistical evaluation 
Statistical evaluation of analytical results is performed with SPSS software 14.0 for Windows (SPSS, 
Chicago, USA). Paired-samples t-tests are performed in order to detect statistically significant 
deviations between the days of hospital admission. Independent-sample t-tests are performed 
between the subgroups; p-values < 0.05 are considered to be statistically significant. Data are 
expressed as mean values ± SD, unless specified otherwise. 
R E S U LTS  
Results for conventional haemocytometric parameters are listed in Table 1.  
Within 24 hours after hospital admission results for Hb are situated within the lower region of the 
reference range interval (male: 137 - 177 g/L, female: 121 - 161 g/L). Until day 4 of hospital 
admission a steady trend towards a decline of 3-8% is established . 
Within the three subgroups (CURB-65 :51, 2 and �3) results for Hb concentration demonstrate a 
decline from admission (137±13, 129±14 and 127±18 g/L respectively) until day 4 (127±11 
(p=o.ooo), 118±14 (p=o.ooo) and 116±13 (p=o,026) g/L respectively). Subjects with higher CURB-
65 scores demonstrate a tendency towards lower Hb concentrations. 
From day 4 a steady trend towards increasing Hb concentrations amounting to 137±13 (p=o.ooo), 
126±10 (p=o.006) and 121±13 (NS) gl/L respectively at day 14 is observed. Decreasing Hb 
concentrations may be explained amongst others by haemodilution. No significant deviations are 
observed for results of mean cell haemoglobin concentration (MCHC). 
Fluctuations of erythopoi:esis activity over time are depicted in Figure 1 (mean values ± SD). In the 
subgroups (CURB-65 :51, 2 and �3) results for absolute reticulocyte counts demonstrate a tendency 
towards increase from day 4 towards 0.055 ± o.021(p=o.001), 0.057±0.014 (p=o.ooo) and 
0.065±0.023 (NS) x1012/L respectively at day 14. 
Results for immature reticulocyte count (IRF) increase steadily from admission towards 
0.0076±0.0044 (p=o.005), 0.0113±0.0062 (p=o.002) and 0.0104±0.0066 (NS) respectively at day 7. 
At day 7 results for IRF decrease slightly towards 0.0043±0.0029 (p=o.ooo), 0.0061±0.0038 (NS), 
and 0.0083±0.0052 (NS) x1012/L respectively at day 14. 
Results concerning Ret-He fluctuations are represented in Figure 2 (mean values ± SD). With 
regard to initial measurements within 24 hours after hospital admission Ret-He values are situated 
within the lower region of the reference range interval (30.4-36.8 pg). Results for Ret-He in the 
subgroups demonstrate a decline of 3-8% (NS) within the time period elapsing from hospital 
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admission (31.6±2.4, 30.8±2.9 and 32.3±4.5 pg respectively) until day 4 (30.7±3.2 (NS), 29.3±3.6 
(NS) and 29.6±3.4 pg (NS) respectively). After reaching a minimum RET-He value at day 4 an 
increasing trend towards values within the reference range to 35.5±2.0 (p=o.ooo), 34.7±2.5 
(p=o.ooo) and 34.0±2.3 (p=o.001) pg respectively is observed at day14. 
In contrast, no shift is detected when concerning results for RBC-He content (Figure 2). 
For results concerning RET-He/RBC-He ratio a similar longitudinal pattern is demonstrated. 
Within 24 hours after admission results for RET-He/RBC ratio are decreased ( 0.99± 0.07, 0.97±0.16 
and 0.97±0.11 respectively). Until day 4 a further decrease to 0.95±0.07 (NS), 0.92±0.08 (NS) and 
0.91±0.08 (NS) respectively is observed. From day 4 a steady trend to increase towards 1.10±0.02 
(p=o.ooo), 1.10±0.02 (p=o.ooo) and 1.06±0.05 (p=o.ooo) respectively at day 14 is observed. 
At hospital admission PCT concentrations are obviously increased (2.6±6.2, 6.2±5.5 and 16.1±11.6 
ug/L respectively). Due to treatment with antibiotics a steady trend to decrease towards the 
reference range ( < 0.05 ug/L 1°) is demonstrated for PCT-results at day 14 (0.05±0.03 (p=o.012), 
0.06±0.03 (p=o.036)and 0.06±0.03 ug/L (p=o.036) respectively (Figure 3). Declining results are 
indicative for reduction of inflammation activity due to beneficial response to treatment with 
antibiotics. 
D I S CU SS I ON 
The anaemia of inflammation is in part due to a disturbance of systemic iron utilization.. In 
pathological conditions, temporarily decreased haemoglobin synthesis may be due to reduced iron 
availability to the developing erythron1 ;P 1; 12 
Pro-inflammatory cytokines and cells of the reticuloendothelial system induce changes in iron 
homeostasis. Availability of iron is thought to be of vital importance for tissue proliferation of 
micro organisms because it is an essential nutrient for enzyme activity in the citric acid cycle, 
mitochondrial respiration, DNA synthesis and oxygen transport systems. Sequestration of iron 
from micro organisms into the reticuloendothelial system implies a protective strategy for 
inhibiting the growth of pathogens. 
Haemocytometric parameters assessing the effects of poor iron supply for Ret-He have been 
recently introduced. RET-He is demonstrated to be a sensitive indicator for monitoring short term 
deteriorations in functional iron supply for erythropoiesis13;14.ln case of apparently healthy subjects 
Ret-He results exceed results of RBC-He amounting to 5 -15%. 
A temporarily decreased degree of haemoglobinization is inferred from corresponding shifts in 
MCV values with decreased values for Ret-He and Ret-He/RBC-He ratios respectively15 • If 
compared with interpretation of RBC counts, Ret-He yields an immediate indication concerning 
the actual shift of iron availability for haemoglobinization in erythroid precursors. 
In case of immune activation iron suppletion induces production of highly toxic hydroxyl radicals 
which may cause tissue damage and endothelial dysfunction and an increased risk of acute 
cardiovascular events4• Iron suppletion is inappropriate in case of subjects with acute 
inflammation 1; 16 
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Conclusion 
Results of our study demonstrate a temporary impairment of Ret-He in subjects with community­
acquired pneumonia. After onset of pneumonia decreased results of Ret-He and Ret He/RBC-He 
ratio occur, reflecting acute erythropoietic changes which may be due to functional iron 
deficiency. 
Recently it has been established that iron redistribution during inflammation is primarily regulated 
by the hepatocellular peptide hormone hepcidin16• 
The effect of hepcidin will be investigated in a next study. 
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Introduction 
Patients with community acquired pneumonia (CAP) often exhibit a declining haemoglobin 
(Hb) concentration. During inflammation pro-inflammatory cytokines and cells of the 
reticuloendothelial system induce disturbances in iron homeostasis. In this study inflammation 
markers and hepcidin concentrations were monitored together with short-term alterations in 
reticulocyte haemoglobinization (RET-He). 
Methods 
2 5 patients with CAP participated in the study. 
Results 
At hospital admission serum hepcidin concentrations (14.6±6.9 nMol/L, mean±SD) were situated 
in the upper level of the reference range (0.5-13.9 nMol/L). Results for C-reactive protein (CRP) 
and Interleukin-6 (IL-6) were obviously increased compared to the reference ranges. From 
admission until day 14 hepcidin, CRP and IL-6 steadily decreased towards the reference ranges. 
Results for Hb demonstrated a decline from admission until day 4 from 8 .1± 1.0 mMol/L to 7 .4±0.9 
mMol/L. From day 4 Hb-values increased towards 8.o±o.8 mMol/L at day 14. At admission 30% of 
the patients demonstrated Hb results below the reference range. At admission Ret-He results were 
within the lower region of the reference range. Until day 4, a further decline of 3-8% was established. 
During antibiotic treatment reticulocyte count increased from 0.041±0.017 x1012/L at day 4 to 
0.055±0.021 x1012/L at day 14. Within this period Hb and Ret-He results recovered towards the 
reference ranges 
Conclusion 
Results of our study demonstrated a transient increase of cytokine stimulated serum Hepcidin in 
patients with CAP. After onset of pneumonia obviously increased results for hepcidin were 
observed supporting the hypothesis that hepcidin induced transient impairment of RET-He may 
be due to iron deprivation. 
I N T R O D U CT I O N  
The condition indicated as the anaemia of inflammation refers to subjects with acute or chronic 
immune activation. A protective mechanism, including withdrawal of iron from the blood 
circulation as an essential growth factor of pathogens, is hypothesized to prevent pathogens from 
invading organs while increasing the efficacy of cell mediated immunity1 3• In the pathophysiology 
of inflammation iron homeostasis is deteriorated by increased uptake and increased storage of iron 
within cells of the reticulo endothelial system. As a result iron restricted erythropoiesis occurs 
because of decreased availability of iron for Hb-synthesis in the erythron2 • 
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Iron redistribution during inflammation is amongst others effected by the hepatocellular peptide 
hormone hepcidin. The name implicates an indication for the antimicrobial activity of the peptide4• 
In case of inflammation hepcidin synthesis is superseded by the upregulatory effects of several 
cytokines. The most important cytokine inducing hepcidin synthesis is IL-6. Increased storage of 
reticulo endothelial macrophage iron coincides with an increased serum hepcidin concentration, 
decreased dietary iron absorption and decreased circulating iron. Hepcidin inhibits the release of 
iron in reticule endothelial macrophages by binding to the cellular iron exporter ferroportin 
(figure 1)3;5;6• 
We hypothesize that transient reduction of haemoglobin synthesis in patients with acute 
inflammation due to CAP corresponds with increased hepcidin concentrations. The aim of this 
study was to elucidate the pathophysiology of iron deprivation yielding short term alterations of 
haemoglobinization by simultaneously monitoring hepcidin and biomarkers regarding infection 
in patients with CAP. 
Figure 1. The role ofhepcidin in iron metabolism. Hepcidin-ferroportin interaction determines the flow of iron into plasma. 
Hepcidin concentration is in turn regulated by iron, erythropoietic activity and inflammation. 
From: Nemeth E, Ganz T: Acta Haematol 2009 ( 6) 
Duodenum 
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M ET H O D S 
Study design 
Patients with a medical history combined with clinical and radiological findings consistent with 
CAP requiring hospitalization were enrolled in the study. Inclusion criteria were written informed 
consent, age �18 years, new consolidation(s) on the chest radiograph and clinical presentation of 
acute illness with one or more of the following symptoms indicating CAP: temperature �38°C, 
dyspnoea, cough (with or without expectoration of sputum), chest pain. 
Exclusion criteria were pregnancy or lactation, severe immunosuppression, neoplastic disease, any 
condition requiring corticosteroid treatment prior to admission for pneumonia, pneumonia which 
developed within 8 days after hospital discharge and obstruction pneumonia ( e.g. due to lung 
cancer). At hospital admission severity of illness was evaluated by application of the CURB-65 
score7 • Patients were classified into three subgroups, with CURB-65 scores �1 (n=12), 2 (n=8), and 
�3 (n=5) respectively. The CURB-65 score is an index for CAP severity classification considering 
degree of confusion, blood urea nitrogen concentration, respiratory rate, blood pressure and age 
6 5 or older. During hospitalisation patients received antibiotics treatment for seven days according 
to locally applicable guidelines8• Patients were monitored daily with regard to clinical stability. 
Laboratory investigations were performed at hospital admission and subsequently once a day until 
day 7. The final measurement was performed at day 14. The present study is a part of a larger 
study9• The study protocol was approved by the local medical ethics committee. 
Preparation of blood samples 
The total amount of blood drawn for laboratory tests during the integral study is estimated to be 
approximately 1 00 mL. Blood samples were drawn into Vacutainer• tubes, anticoagulated with 
K2EDTA (Becton Dickinson, Plymouth, UK) and plain tubes (Vacutainer SST, Becton Dickinson, 
Plymouth, UK). Blood samples were analyzed within 4 hours after collection. Serum samples were 
stored in aliquots at -20°C until analysis for investigation of biochemical parameters reflecting 
activity state of infection. 
Serum Hepcidin-25 
Serum hepcidin concentrations were established by application of a combined methodology of weak 
cation exchange chromatography and time-of-flight mass spectrometry (TOF MS). An internal 
standard ( synthetic hepcidin-24; Peptide International Inc.) was applied for quantification 10• Peptide 
spectra were generated on a Microflex LT matrix-enhanced laser desorption/ionization TOF MS 
platform (Bruker Daltonics). The median level of serum hepcidin-25 in a reference subjects group 
amounted to 4.2 nMol/L, range 0.5 - 13.9 nMol/L1 1 • The analyses were performed in the Department 
of Laboratory Medicin of the Radboud University (Nijmegen, The Netherlands). This laboratory is 
particularly renowned for its knowledge and outstanding expertise with regard to hepcidin. 
Biomarkers reflecting inflammatory state of infectious disease 
Concentrations of CRP were established on a ProSpec nephelometer according to the 
manufacturer's instructions (Siemens Healthcare Diagnostics, Deerfield IL, USA). Serum IL-6 
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concentrations were established on a Beckman Access analyzer using the Access IL-6 reagent 
(Beckman Coulter Inc., Fullerton, USA). 
Haemocytometry 
Haemocytometric parameters were established by measurement on a SysmexXE-21 oo Haematology 
Analyzer (Sysmex Corporation, Kobe, Japan). Methodology of reticulocyte counting is based on 
automated fluorescent flowcytometry utilizing a polymethine dye for binding cytoplasmic RNA. 
The mean forward light scatter intensity in the reticulocyte channel is estimated as a measure for 
the particle volume and Hb content of RB Cs and reticulocytes respectively. Results concerning Hb 
content are initially reported as RBC-Y for RBCs and RET-Y for reticulocytes. Subsequently, 
algorithms y=4oo*e0·0009'Ret-Y and y=4oo*eo.ooo9'RBC-Y are applied to transform arbitrarily reported 
channel numbers of the RET-Y and RBC-Y into haemoglobin content equivalents 12• Haemoglobin 
contents in reticulocytes and RBCs are expressed in attomol and denoted as RET-He and RBC-He 
respectively. 
Statistical evaluation 
Statistical evaluation of results was performed with application of SPSS software 14.0 for Windows 
(SPSS, Chicago, USA). Data were expressed as mean values ± SD, unless specified otherwise. 
Paired-samples t-tests were performed to detect statistically significant deviations in results of 
analyses between the days of hospital admission. Independent-sample t-tests were performed 
between the subgroups with increasing CURB-65 scores. A p-value < 0.05 was considered to be 
statistically significant. 
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R E S U LTS  
Twenty-five patients (male n=12, female n=13) were enrolled in the study. Classification for 
severity of illness resulted in three subgroups with CURB-65 scores �1 (n=12), 2 (n=8), and 2?:3 
(n=5) respectively. Parameters including hepcidin concentrations, actual state of inflammation 
and the amount of RBC and reticulocyte haemoglobinisation were not significantly different 
between the subgroups with increasing CURB-65 scores (data not shown). 
With regard to initial measurements at hospital admission mean values for hepcidin concentrations 
were situated near the upper level of the reference range (0.5-13.9 nMol/L). Results for hepcidin 
decreased steadily from 14.6±6.9 nMol/L on the day of hospital admission towards 7.6±3.7 nMol/L 
(p=o.024) at day 4 and 3.6±3.1 nMol/L (p=o.037) at day 14 (figure 2). 
Results (Mean ± SD) for serum hepcidin concentration (nMol/L) which have been established in 
25 patients at hospital admission (day 1), at several days during antibiotic treatment (day 2, 3, 4) 
and after completion of antibiotic treatment (day 14). The horizontal lines indicate the lower and 
upper level of the reference range for apparently healthy subjects (0.5-13.9 nMol/L). The horizontal 
dashed line indicate the median value for apparently healthy subjects (4.2 nMol/L). 
At hospital admission CRP and IL-6 concentrations were obviously increased (table 1). CRP- and 
IL-6 concentrations demonstrated a steadily ongoing decrease from the day of admission until day 
14 towards the reference ranges (CRP <s mg/L, IL-6 <10 ng/L). Results for haemocytometric 
parameters are listed in table 2. Results for Hb concentration demonstrated a decline from 8.1±1.0 
mMol/L at admission to 7.4±0.9 mMol/L on day 4 (p=<o.001). From day 4 onwards a steady trend 
towards higher concentrations was observed, reaching a level of 8.o±o.8 (p=<o.001) mMol/L at 
day 14. 
Results concerning fluctuations of Ret-He within a time period elapsing 2-weeks are represented 
in figure 3A (mean values ± SD). With regard to initial measurements within 24 hours after hospital 
admission mean Ret-He values were situated within the lower region of the reference range interval 
(1900-2300 aMol). Results for Ret-He demonstrated a decline amounting to 3-8% (NS) within the 
time interval from admission 1931±241 aMol until 1845±199 aMol (NS) at day 4. After reaching a 
minimum RET-He value at day 4 results steadily increased towards the reference range reaching 
2129±136 aMol (p=<o.001) at day 14. 
In contrast, for RBC-He content no shift was detected within the time interval between admission 
(2020±135 aMol) and day 14 (1972±120) aMol (NS) (figure 3B). 
Within 24 hours after admission results for RET-He/RBC-He ratio were obviously decreased 
(0.96±0.12). Until day 4 a further decrease to 0.93±0.07 (NS) was observed. From day 4 onwards a 
steady trend to increase was observed reaching a mean level amounting to 1.08±0.04 (p=<o.001) 
at day 14 (figure 3C). 
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Table 1. Levels of CRP and IL-6 during treatment 
parameter 
CRP - mg/I 
l l-6 -ng/I 
Day 1 Day 4 Day 14 









CRP: C-reactive protein; IL-6: interleukin-6. 













••••• - . . . . . t .  ., • •  ., ., . . 
4.33±0.45 3 .98±0.5 4.27±0.37 
<0.001 <0.001 
(2.91-5.14) (2.47-4.84) (3 .80-5.25) 
8 .1±1.0 7.4±0. 9  8.0±0. 8  
<0.001 <0.001 
(5 .5-0 .0) (5 .0-8.9) (6. 9-9 .8) 
90.0±5.3 90.5±4.9 91.5±4. 6  
NS  NS  
(82 .3- 03.9) (82 .2-102.9) (85.11-03 .5) 
20.9±0.8 20.7±0.7 20.5±0.5 
0 .019 NS 
(19 .7-22.6) (19 .5-22.4) (19 .7 - 21.4) 
46.7±4.3 47.2±3 .9 47.5±3 .9 
NS NS 
(39 .9-53 .4) (42.0-54.0) (41.5-56.5) 
0.044±0.015 0 .041±0.017 0.055±0.021 
(0.015- (0 .0157- (0 .0159- NS 0.02 
0.0797) .0819) 0.1198) 
Male 
4.5-5. 5  
Fema le  
4.0-5 .0 
Ma le  
8 .5-11.0 
Fema le  






Fema le  
0.030-0.085 
RBC: red blood cell count; Hb: haemoglobin; MCV: mean corpuscular volume; MCHC: mean corpuscular hemoglobin 
concentration; RDW-SD: red cell distribution width-standard deviation. NS = Statistically not significant. 
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Figure 3A. Ret-He values during days of treatment 
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Results (Mean ± SD) for reticulocyte haemoglobin content (RET-He, aMol A), red blood cell 
haemoglobin content (RBC-He, aMol, B) and Ret-He/RBC ratio C) which have been established 
in 25 patients at hospital admission (day 1) ,  at several days during antibiotic treatment (day 2, 3, 4) 
and after completion of antibiotic treatment (day 14). The horizontal lines indicate the lower and 
upper level of the reference range for apparently healthy subjects. 
D I S C U S S I O N  
Anaemia during acute systemic inflammation is a frequently encountered clinical problem. The 
aim of the study was to elucidate a short-term arrest in haemoglobinization by simultaneously 
monitoring of biomarkers regarding severity of infection and hepcidin concentrations in patients 
with CAP. Our study revealed that results for CRP, IL-6 and hepcidin concentrations were obviously 
increased at hospital admission. Due to treatment with antibiotics CRP, IL-6 and hepcidin results 
steadily declined until day 14, indicating reduction of inflammation activity and physiological 
stress. After hospital admission results for Ret-He and Ret- He/RBC-He ratio decreased within 
several days after onset of pneumonia. After reaching a minimum RET-He value at day 4 an 
increasing trend towards results within the reference range was observed. These findings reflect 
sudden erythropoietic arrest which might amongst others be partly due to functional iron depletion 
during inflammation. The anaemia of inflammation is to a certain extent due to a disturbance of 
iron utilization in which case iron is sequestered in activated macrophages, enterocytes and 
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hepatocytes. Due to limited availability of iron to maturing reticulocytes Hb synthesis is impaired. 
Decreased haemoglobinization is concluded from interpretation of haemocytometric parameters 
established in RBCs and reticulocytes in peripheral blood. In case of subjects with an anaemia of 
inflammation, results of Ret-He and Ret-He/RBC-He ratio combined with conventional parameters 
like mean cell volume (MCV), Haemoglobin (Hb ), mean cell haemoglobin concentration (MCHC) 
and red blood cell distribution width (RDW-SD) should be considered in order to achieve an 
appropriate clinical interpretation with regard to deviations in Hb synthesis13 · 1 5• In the present 
study results for mean hepcidin concentrations were situated near the upper level of the reference 
range. Results for hepcidin declined steadily until day 14. In case of inflammation hepcidin release 
is induced by cytokines, in particular IL-6. An increase in hepcidin concentration will induce an 
increase of reticuloendothelial macrophage iron. Redistribution of iron is initiated by cytokine­
stimulated hepcidin synthesis which induces loss of ferroportin from macrophage and enterocyte 
cell membranes and trapping of iron. Sequestration of iron restricts its availability for haemoglobin 
synthesis3;5 ; 16• Recently Van Eijk et al.4 suggested that hepcidin release is a modulator of anaemia in 
septic patients with systemic inflammation. Hepcidin induces a direct inhibitory effect on 
erythropoiesis. 
At admission, results for CRP and IL-6 serum concentrations were obviously increased compared 
to the reference ranges. From the day of admission until day 14 CRP and IL-6 concentrations 
demonstrated a steady trend to decrease towards the reference range. Declining values are indicative 
for reduced inflammatory activity indicating a positive response to treatment with antibiotics. 
With regard to Hb concentration results below the reference range were observed in 30% of the 
patients. For Hb concentrations no statistically significant deviation between the subgroups could 
be detected within 24 hours after admission. Obviously decreased Hb concentrations were observed 
within the subgroup of patients with CURB-score �3, which might be associated with the severity 
of inflammation. Several investigators reported decreased Hb concentrations in up to 30% of 
patients with CAP4; i7- i9 _ The phenomenon of decreased Hb concentrations was associated with 
poor prognosis and increased mortality in patients admitted with CAP20• In another study a 
decrease in Hb concentration amounting to 0.3 mMol/L/day has been demonstrated during the 
first days of stay in the intensive care unit21 • Steadily decreasing Hb concentrations during 
hospitalization are probably due to combined effects of haemodilution, inhibition of erythropoietin 
production, blunted erythropoietic response, reduced lifespan of RBCs during inflammation and 
frequent phlebotomy for diagnostic testing. Mean results for RDW-SD were situated near the 
upper level of the reference range and demonstrated a slight but not statistically significant increase 
from admission until day 14. Results for RDW-SD were more pronounced increased in the patients 
with the highest category of CURB-scores. Several investigators hypothesized that increased levels 
of RDW correspond with an inflammatory state, which is associated with a significant increase in 
complications during hospitalization and 90-day mortality rates regardless of haemoglobin 
concentrations. Increased RDW values occur as a result of ineffective RBC production due to 
cytokines blocking activity of erythropoietin22 • However, in our study we were not able to confirm 
the hypothesis probably because of the limited amount of patients. 
With regard to evaluation of the initial measurements within 24 hours after hospital admission 
mean Ret-He values were situated within the lower region of the reference range interval. Results 
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for Ret-He demonstrated a short term decline starting at admission. After day 4 a steady trend 
towards values within the reference range was observed until day14. RET-He has been demonstrated 
to be a sensitive indicator for monitoring short term deteriorations in functional iron supply for 
erythropoiesis13 ;14 • Our findings contribute to understanding of the pathophysiology of Hb­
synthesis in patients with CAP and may have important clinical implications. Awareness that Hb 
concentrations may decline even without active bleeding or haemodilution may eliminate the need 
for repeated diagnostic testing in patients with CAP. 
In conclusion results of this study demonstrate a temporary increase of cytokine stimulated serum 
Hepcidin concentrations in combination with a temporary decrease of Hb and Ret-He immediately 
after onset of pneumonia. Our results support the hypothesis that hepcidin induces transient 
impairment of reticulocyte haemoglobin content (Ret-He) in patients with CAP. 
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C H A PT E R  7 
Sum ma ry 
In this thesis several possible intervention strategies are explored for improving outcome in 
hospitalised patients with community-acquired pneumonia (CAP). 
COPD as co-morbidity in patients with CAP. 
In patients with CAP several co-morbidities can increase mortality. COPD is one co-morbidity 
often present in patients with CAP of which it is uncertain whether it increases the mortality risk. 
Several studies found a higher mortality in patients with both CAP and COPD. In Chapter 1 data 
is presented which demonstrates the influence of COPD on patients with CAP. One of the most 
striking findings of this study is the reclassification of COPD as co-morbidity by using pulmonary 
function testing (PFT). Almost 70 % of included patients had one or more co-morbidities. COPD 
was found as a co-morbidity in 36.3 % of the patients. The diagnosis was confirmed by PFT 
according to the GOLD guidelines. However in nearly 20 % of the patients no PFT were available 
due to lost to follow or death. By means of pre-admission PFT COPD was identified in 6 patients. 
Of the 95 (36.3%) patients with COPD according to chart review, medical history or information 
pre-admission, only in 66 (69.5%) patients the diagnosis was confirmed with PFT during follow 
up. While 29 patients were reclassified as having no COPD, in 29 other patients without diagnosis 
of COPD prior to admission, the diagnosis was made during follow up by means of PFT. 
Approximately one third of the patients were reclassified according to their COPD status. Mortality 
in this study was slightly, although not significantly lower in the non-COPD group (8 [8.4%] 
patients) than in the COPD group (20 [12.0%]  patients, p=o.37). Patients with COPD did have a 
more severe CAP than non-CO PD patients according to the PSI. The CURB-65 score did not differ 
between the two groups. The reasons for the higher PSI classes were a higher age and higher 
number of males, next to a higher blood rate at admission. 
Role of corticosteroids in the treatment of patients hospitalised with CAP. 
The use of corticosteroids as an adjunctive treatment in patients with CAP is not a new concept. 
The first studies using prednisolone in patients with pneumococcal pneumonia date from the 
195o's. In some recent publications it has been shown that patients with severe CAP might be 
benefit by corticosteroids. In Chapter 2 a randomised clinical trail is presented. In this trial 213 
patients hospitalised with CAP were randomised between antibiotic therapy according to current 
guidelines in combination with prednisolone (od 40 mg for 7 days) and antibiotic therapy 
according to current guidelines with placebo. Patients in the prednisolone group did have a higher 
level of C-reactive protein (CRP) at admission, but overall the groups were balanced. The primary 
endpoint was clinical cure at day 7. In the prednisolone group 84 (80.8%) patients had a clinical 
cure at day 7 while in the placebo group 93 (85. 3%) patients had a clinical cure at day 7 (p=o.38). 
The secondary endpoint clinical cure at day 30 was reached in 93/109 (85.3%) in the prednisolone 
group and 84/109 (77.1 %) of the subjects receiving placebo (p=o.08). Patients on prednisolone 
had a faster defeveresence and faster decline in serum CRP levels compared to patients who had 
placebo. There was also no differences in length of stay (LOS) and time to clinical stability (TTCS) 
Sub-analysis of patients with severe pneumonia did not show differences in clinical outcome. Late 
failure (>72 hours after admittance) was more common in the prednisolone group (20 (19.2%)) 
than in placebo-treated patients (10 [6.4%],  p=o.04). This was mainly due to more need for extra 
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antibiotics and prednisolone. Adverse events in this study were few and did not differ between the 
two groups. 
Influence of prednisolone on CRP and PCT in patients with CAP 
Corticosteroids have multiple effects on pro-inflammatory and anti-inflammatory cytokine. There 
is a paucity of data on the expression of CRP and PCT under influence of corticosteroids, while 
these biomarkers are increasingly used for initiating and monitoring treatment of patients with 
CAP. The effects of prednisolone on CRP, PCT and white blood cell count (WBC) in patients 
hospitalised with CAP are described in Chapter 3. In 176 out of 213 patients data on CRP, PCT 
and WBC were available. In patients with severe CAP (CURB-65 � 3) CRP and PCT levels were 
higher (260±146 mg/I versus 230±151 mg/I, p=o.25 and 23.26±32.08 µg/1 versus 4.69±8.84 µg/1, 
p<o.01). Patients with clinical success had lower CRP levels (225±145 mg/I versus 270±160 mg/I, 
p=o.09) and significantly lower PCT levels (6.94±13.08µg/l versus 15 .60±29.27µg/l, p=o.01) on 
admission. Patients with clinical success at day 30 had higher differences in CRP and WBC during 
treatment with antibiotics and prednisolone, but not in PCT levels. 
Patients with clinical failure with antibiotics and prednisolone had a marked decline in CRP 
(L\day1-day3 118±148 mg/1), while patients with clinical failure with antibiotics alone had an 
increase in CRP (Liday1-day3: -18±169 mg/I, p<o.01). Admission biomarkers levels, decline of 
biomarkers or prednisolone were not independently associated with clinical failure. Based on 
these findings it can be concluded that prednisolone has a marked influence on the expression of 
CRP in patients with CAP, but not on the expression of PCT. 
Prognostic role of D-dimer levels in patients with CAP 
Several biomarkers have prognostic value in the evaluation of patients with CAP. Most of these 
biomarkers are related to the inflammation cascade in patients with CAP. However the coagulation 
pathway is also influenced by CAP. Some earlier studies show that D-dimer levels, products of 
fibrin degradation, may be useful in the evaluation of patients with CAP. In Chapter 4 serial 
D-dimer levels were examined in 147 patients hospitalised with CAP. D-dimers levels at admission 
were higher in patients with severe CAP (2166±1258 versus1630±1197 µg/1, p=o.03), with clinical 
failure at day 30 (2228 ±1512 versus1594±1078 µg/1, p=o.02) and with early (< 72h) failure 
(2499±1817 µg/1 versus 1669±1121 µg/1, p=o.01). Non-survivors had higher D-dimer levels 
(3025±2105 versus 1680±1128µg/l, p=o.05). None of the 16 patients with D-dimer levels < 500 
µg/1 died. In multivariate analysis D-dimer levels were not associated with clinical outcome. 
D-dimer levels have poor accuracy for predicting clinical outcome at day 30 (AUC 0.62, 95% CI 
0.51-0.73) or 30 day mortality (AUC 0.71 (95 %  CI 0.51-0.91). Addition of D-dimer levels to 
CURB-65 did not increase the accuracy. Also no reclassification of patients into a higher or a lower 
risk group occurred when using the Net Reclassification Index. No differences were observed in 
serial D-dimer levels between patients with clinical success or failure at day 30. 
Haemoglobin arrest in CAP 
In Chapter 5 functional iron deficiency is demonstrated in 75 patients with CAP. Deviations in 
reticulocyte haemoglobin content (Ret-He) were investigated together with inflammation markers 
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in patients with CAP. Also short-term alterations with regard to Ret-He during and after completing 
antibiotic treatment were investigated. 
The 75  patients were divided in three subgroups based on the CURB-65 scores of ::;1, 2 or �3-
In all of the three subgroups, Hb results demonstrated a decline from the day of admission until 
day 4. From day 4 an increase towards higher values was observed at day 14. 
Within 24 hours after admission Ret-He results were situated within the lower quartile region of 
the reference range interval. Until day 4 of hospital admission a steady trend towards a decline of 
3-8% was established. During antibiotic treatment an increase of reticulocyte count occured from 
0.039±0.014 1012/L at day 4 to 0.057±0.020 1012/L at day 14 (mean ± SD). Recovery of Hb and 
Ret-He occurred towards values within the reference range. 
The acute inflammation in patients with CAP results in impairment of RET-He at an early stage. 
After onset of pneumonia decreased results ofRet-He and Ret He/RBC-He ratio were demonstrated, 
reflecting acute erythropoietic dysfunction which could in part be explained by functional iron 
depletion. 
Hepcidin in CAP 
Hepcidin plays a pivotal role in the iron metabolism. In Chapter 6 the role of hepcidin in 2 5 
patients with CAP has been investigated. At hospital admission serum hepcidin concentrations 
( 14.6±6.9 nMol/L, mean±SD) were in the upper level of the reference range (0.5 - 13.9 nMol/L). The 
levels of CRP and Interleukin-6 (IL-6) were also increased compared to the reference ranges. From 
admission to day 14 hepcidin, CRP and IL-6 steadily decreased towards the reference ranges. Hb 
values demonstrated a decline from admission to day 4 from 8.1±1.0 mMol/L to 7-4±0.9 mMol/L. 
From day 4 Hb values increased towards 8.o±o.8 mMol/L at day 14. At admission 30% of the 
patients had Hb concentrations below the reference range. At admission the Ret-He results were 
within the lower region of the reference range. Until day 4 a further decline of 3-8% was established. 
During antibiotic treatment reticulocyte count increased from 0.041±0.017 x1012/L at day 4 to 
0.05 5±0.021 x1012/L at day 14. Within this period Hb and Ret-He results recovered towards the 
reference ranges. The temporary increase of hepcidin, along with IL-6 and CRP, support the 
hypothesis that hepcidin induces transient impairment of reticulocyte haemoglobin content (Ret­




C H A PT E R  8 
Dutch s umma ry 
N E D E R L A N D S E S A M E N VATT I N G  
In <lit proefschrift is nader gekeken naar de mogelijkheden van het behandelen van patienten met 
een buiten het ziekenhuis opgelopen longontsteking (community-acquired pneumonia, CAP). De 
nadruk van <lit proefschrift ligt op de ontstekingsreactie die optreed bij een longontsteking, de 
behandeling van deze ontstekingsreactie en de mogelijkheden van het 'monitoren' van de effecten 
van de behandeling van een longontsteking. 
In de introductie is een korte samenvatting gegeven van de afweerreactie bij patienten met een 
longontsteking. 
In het eerste hoofdstuk staat de ziekte COPD (chronisch obstructief longlijden) centraal. Vanwege 
aanwijzingen uit eerdere onderzoeken <lat patienten met COPD mogelijk een hogere kans op 
overlijden hebben als ze een longontsteking oplopen is een grate groep patienten die zijn behandeld 
voor longontsteking nader bekeken. Deze patienten deden mee aan een onderzoek waarbij twee 
verschillende behandelstrategieen met antibiotica werden vergeleken. Hierbij is waar mogelijk ook 
longfunctieonderzoek verricht. Longfunctieonderzoek is noodzakelijk voor het objectief vasts tell en 
van de diagnose COPD. In eerdere onderzoeken ontbreken vaakgegevens over longfunctieonderzoek 
omdat <lit niet eerder was verricht bij de patienten die ge'includeerd waren in deze onderzoeken. 
Veelal werd de diagnose COPD dan gesteld op klachtenpatroon, voorgeschiedenis of het gebruik 
van bepaalde medicatie gericht tegen COPD. Een van de belangrijke punten van hoofdstuk een is 
het feit dat door gebruik van longfunctieonderzoek voor de diagnose van COPD ongeveer eenderde 
van de patienten die op andere criteria de diagnose COPD hadden gekregen, juist geen COPD 
hadden. Echter hetzelfde aantal patienten bleek juist bij longfunctieonderzoek wel COPD te 
hebben terwijl <lit van te voren niet bekend was. De kans op overlijden als gevolg van de 
longontsteking is in deze zeer goed beschreven groep patienten niet hoger als de patient ook COPD 
heeft. Tevens bleek <lat het gebruik van twee in de klinische praktijk veel gebruikte modellen om de 
kans op overlijden in te schatten, de PSI en de CURB-65, goed mogelijk blijft bij patienten met 
COPD die ookeen longontstekinghadden. Erwaren weliswaarverschillen in patientkarakteristieken 
tussen patienten met en zonder COPD, maar deze verschillen waren niet significant van belang bij 
het gebruik van deze modellen. Een mogelijke reden waarom de uitkomsten van patienten met 
COPD en een longontsteking niet verschillen van uitkomsten van patienten met een longontsteking 
zonder COPD is het gebruik van corticostero'iden. In deze studie kreeg ruim driekwart van de 
patienten met COPD ook corticostero'iden tegenover een kwart van de patienten zonder COPD. 
Het gebruik van corticostero'iden, zoals prednisolon kan leiden tot een verminderde 
ontstekingsreactie en daardoor tot een mogelijk betere uitkomst. 
In het tweede hoofdstuk is een dubbelblind gerandomiseerd onderzoek beschreven waarbij 
patienten met een CAP naast de gebruikelijke behandeling ook prednisolon of placebo kregen. De 
uitkomstmaat was het klinisch herstel na 7 dagen. Uit de resultaten van deze studie komt naar 
voren <lat het toevoegen van prednisolon geen verbetering geeft van het percentage patienten met 
een goed klinisch herstel. Ook op andere uitkomstmaten zoals duur van ziekenhuisopname, 
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klinisch herstel na 30 dagen en overlijden werd geen verschil gevonden. Wel viel op dat in de groep 
patienten die met prednisolon werd behandeld vaker een laat falen optrad. Dit laat falen kwam 
meestal doordat deze patienten extra antibiotica of prednisolon nodig hadden tijdens of net na 
hun ziekenhuisopname. De bijwerkingen van de behandeling met prednisolon vielen mee en 
waren vergelijkbaar met de bijwerkingen van de patienten die met placebo waren behandeld. 
In hoofdstuk drie is de invloed van prednisolon op ontstekingswaarden beschreven. Twee veel 
gebruikte ontstekingswaarden (C-reactive protein, CRP en procalcitonine, PCT) zijn samen met 
leukocyten dagelijks gemeten gedurende de eerste 7 dagen tijdens opname en op dag 14 in 176 
patienten met een longontsteking. De waarden van zowel CRP en PCT daalden geleidelijk over de 
dagen bij zowel patienten die met antibiotica alleen waren behandeld als bij patienten die met 
antibiotica en prednisolon waren behandeld en bij patienten die zowel een goede als slechte 
klinische uitkomst hadden op dag 30. De daling van het CRP is echter sneller bij de behandeling 
met zowel antibiotica als prednisolon. Bij patienten met een slechte klinische uitkomst daalt het 
CRP onder invloed van prednisolon in de eerste paar dagen van behandeling wat een gelijk patroon 
is als bij patienten met een goede klinische uitkomst. Bij patienten met een slechte klinische 
uitkomst die niet met prednisolon werden behandeld is in de eerste paar dagen van behandeling 
geen daling te zien. PCT daalt gelijkmatig zowel bij de groep die met antibiotica en prednisolon 
werd behandeld als bij de groep die met antibiotica werd behandeld. Bij de leukocyten is alleen een 
daling zichtbaar bij behandeling met alleen antibiotica. Bij het gebruik van antibiotica en 
prednisolon blijven de waarden van de leukocyten onveranderd licht verhoogd bij patienten met 
een slechte klinische uitkomst op dag 30. De conclusies van dit onderzoek zijn dan ook dat 
prednisolon een sterk effect heeft op de CRP waarden tijdens de behandeling van een longontsteking. 
CRP kan hierdoor niet gebruikt worden om het effect van de behandeling van een longontsteking 
te beoordelen als de patient ook prednisolon gebruikt. PCT daarentegen wordt niet be'invloed door 
prednisolon gebruik. 
D-dimeren zijn afbraakproducten van fibrine, wat een belangrijke rol heeft bij stolling. D-dimeren 
zijn meetbaar in het serum. Bij mensen met een longontsteking is naast de ontstekingsreactie ook 
een activatie van het stollingsysteem. De activatie van het stollingssysteem kan zich uiten in een 
verhoogd fibrineverbruik en hierdoor ook een verhoogd D-dimeren gehalte. In hoofdstuk vier is 
gekeken of D-dimeren gecorreleerd zijn met klinische uitkomsten van patienten met een 
longontsteking. De hoogte van het gehalte van D-dimeren correleert matig met klinische uitkomsten. 
Als alleenstaande voorspeller van klinische uitkomsten is het bepalen van D-dimeren minder 
geschikt dan het gebruik van een scoringsmodel (CURB-65 score). Het toevoegen van D-dimeren 
aan de CURB-65 score levert ook geen verbetering van de voorspellende waarde op, wanneer 
bekeken door middel van receiver-operator characteristics. Een andere manier om te kijken of een 
nieuw model een verbetering geeft van een voorspellend vermogen is het berekenen van de Net 
Reclassification Index (NRI). De NRI geeft aan hoeveel patienten meer of juist minder accuraat 
geclassificeerd word en voor hun risico op een bepaalde uitkomst. Ook hierbij gaf het toevoegen van 
de D-dimeren aan de CURB-65 score geen verbetering. Verder had het dagelijks bepalen van 
D-dimeren geen meerwaarde voor het monitoren van de response op de gegeven behandeling. 
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Een ander aspect van longontstekingen is de invloed die een longontsteking uitoefent op het 
bloedbeeld. Bij zowel acute als chronische infecties word bloedarmoede (anemie) gezien. Over de 
bloedarmoede bij chronische ziekten is het een en ander wel bekend. De bloedarmoede bij acute 
infecties is echter maar weinig onderzocht. In zowel hoofdstuk 5 als 6 is onderzocht hoe de 
bloedarmoede bij patienten met een longontsteking in elkaar steekt. In hoofdstuk 5 zijn bij een 
groep van 7 5 patienten met een longontsteking dagelijks bloedafnames verricht. Hierbij valt op <lat 
de inbouw van ijzer in met name jonge rode bloedcellen (reticulocyten) verstoord is. Het herstel 
van de inbouw van ijzer lijkt zich dan in de loop van de dagen te herstellen. In hoofdstuk 6 is in een 
groep van 2 5 patienten met een longontsteking verder gekeken naar de functie van hepcidine in de 
tot stand kerning van deze bloedarmoede. Het hepcidine gehalte in deze groep patienten is dan 
ook hoger op de <lag van opname en daalt gedurende de behandeling. Deze daling is dan ook 
zichtbaar bij het CRP en IL-6 gehalte, beide ontstekingsmediatoren. Deze resultaten ondersteunen 
de theorie <lat de bloedarmoede het gevolg is van het onttrekken van ijzer uit het serum door 
macrofagen (soort ontstekingcel). Hierdoor is de functionele ijzervoorraad verminderd wat 
minder gunstig is voor groei van bacterien. Het verder uitdiepen van de samenhang van hepcidine, 
ontstekingsmediatoren en anemie bij patienten met een longontsteking zal meer inzichten en 





C H A PT E R  9 
Gene ra l  d i scuss ion a n d  
futu re pe rspect ives 
To improve treatment outcome in patients with CAP a better understanding of the host response 
is needed. Better understanding may lead the way to improved monitoring and possible beneficial 
modulation of the host response. In this thesis several small steps have been made on the long road 
toward these goals. 
Not all men are equal in their response to agents causing Community-Acquired Pneumonia (CAP). 
Responses depend on inborn ('nature') as well as environmental ('nurture') factors. The host 
response in CAP is a complex interaction between different inflammatory and coagulation 
pathways, each of which are influenced by different co-morbidities and different aetiologies of 
CAP. The "nature" part consists of host genetic polymorphisms in genes coding for important pro­
inflammatory cytokines such as TNF-a and interleukin-6, while the "nurture" part is a large array 
of environmental and behavioural factors that determine susceptibility and severity such as 
cigarette smoking or COPD. 
AN U N DERSTAN D ING OF "NU RTU RE" 
The role of  COPD as a co-morbidity in patients with CAP 
In the PSI COPD is not included as a risk factor for mortality in patients with CAP1 • The current 
data is also inconclusive whether COPD is to be regarded as a risk factor or even a possible 
protective factor for mortality in patients with CAP2•4• The data in this thesis supports the hypothesis 
that patients with CAP and COPD do not have a higher mortality than patients with CAP without 
COPD. This is in concordance with a large prospective Spanish study by Liapikou5, but in contrast 
with the studies by Rello et al. 2 and Restrepo et al. 3• In the latter two studies no pulmonary function 
tests (PFT) were required for diagnosis of COPD. The differences might well be explained by 
shifting of patients their COPD status after PFT . In a large retrospective audit study, patients with 
COPD and radiological findings consisted with CAP had a higher 30-day and 90-day mortality6. 
After adjusting for imbalances between the group of COPD patients and non-COPD patients the 
RR for 30 day mortality was 1.19 (95% CI 1.01,1.42) and for the 90-day mortality 1.09 (95% CI 
0.96,1.23). However, in another prospective study COPD was associated with higher mortality in 
CAP patients (OR=2.62, 95% CI: 1.08-6.39), although other factors such as renal failure, hypoxemia 
and respiratory rate had a more profound impact on mortality7 • These factors are indeed included 
in the PSI or in the CURB-65 score8 • In this thesis patients with COPD did have a more severe 
CAP than non-COPD patients according to the PSI, whereas the CURB-65 score did not differ 
between the two groups. The reasons for the higher PSI classes were a higher age and more males, 
next to a higher blood rate at admission. 
So the debate whether COPD has to count as a risk factor for mortality in patients with CAP is not 
closed, although the study in this thesis, together with one of the prospective studies which use 
PFT for diagnosis of COPD are the methodological soundest data on this subject. In an editorial 
by Torres and Menendez 9 accompanying the study by Restrepo et al.3 several possible factors are 
mentioned for this effect. The colonisation of lower airways by potential pulmonary pathogen, for 
example H. influenzae, may induce a chronic state of inflammation with a possible beneficial anti-
inflammatory response. The second stated factor may be the concomitant administration of 
corticosteroids in patients with CAP and COPD. 
In sputum of COPD patients higher expression of NF-KB in neutrophils are found 1°. The higher 
expression of NF-KB may lead to reduced apoptosis of neutrophils, although the data is not 
consistent. Decreased apoptosis of neutrophils may lead to a more pronounced inflammation in 
pneumoniau. In patients with CAP and COPD the combined effect of reduced apoptosis from 
COPD as a chronic disease and CAP leads to even more apoptosis and more inflammation 12 • The 
reduction of NF-KB by administration of corticosteroids might be the reason for the balance in 
clinical outcome in patients with CAP with or without COPD. Future studies elucidating the 
inflammatory state in patients with COPD will be insightful in the role of COPD as a co-morbidity 
with a beneficial or detrimental effect. 
MOD U LAT ING TH E H OST RES PONSE 
lnterventional approaches of the inflammation in CAP 
Reducing the excess inflammation caused by CAP may lead to improved clinical outcome. In the study 
by Confalonieri et al. 1 3 the infusion of hydrocortisone in their population with severe CAP admitted 
to the ICU did have a profound effect on the clinical outcome. In the study presented in chapter 2 of 
this thesis no benefit of prednisolone was found with respect to clinical outcomes. The severity of CAP 
might be the clue for identifying subjects who may possible benefit from anti-inflammatory therapy. 
In this thesis a large part of the patients had mild to moderately severe disease in comparison to two 
positive RCT's 13;14• Only 22 out of 2 1 3  patients were admitted to an intensive care unit (ICU) in the 
study described in chapter 2. The higher rate of late failures in the group treated with prednisolone and 
antibiotics implies the suggestion of harm by treatment with prednisolone. There was however a signal 
that the use of prednisolone had a impact on the inflammation. The serum levels of C-reactive protein 
(CRP) declined faster in patients treated with prednisolone. This effects did not translate in an effect 
on clinical outcome. Another randomised clinical trial with a rather similar design as the study 
presented in Chapter 2 did however find a benefit in the corticosteroid-treated group of patients with 
CAP15 • Their primary outcome parameter was length of stay (LOS). Patients treated with dexamethasone 
and antibiotics had a significant reduction of LOS by one day in comparison to patients treated with 
antibiotics alone. This raises the question of meaningful clinical endpoints in clinical trials assessing 
corticosteroid therapy. The most objective endpoint, survival, requires a much larger sized trial. 
Reduction of LOS or clinical success might be subject to bias or influences not related to the treatment 
itself. The clinical benefit of adjunctive corticosteroid therapy in patients not admitted to the ICU is 
not clear. In our opinion, the use of corticosteroids should not be routinely used in this patients group. 
The direction of future studies in this field should therefore focus on understanding the inflammation 
cascade and the effects of corticosteroids on this cascade. Identification of subgroups who potential 
can benefit from corticosteroid therapy is also needed. Furthermore good surrogate endpoints are 
warranted in future clinical trials evaluating adjunctive therapy, whether it be with corticosteroids or 
any other agents aimed to intervene in the inflammation cascade. 
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M O N I TO R I N G  T H E H O ST R E S P O N S E  
0-dimer as biomarker in CAP 
Coagulopathy is a universal host response to infection16• In almost all patients with severe sepsis 
serum D-dimer levels are elevated above normal levels. In CAP more than 75 % of the patients have 
elevated D-dimer levels17;18• Also the serum D-dimer levels are correlated with clinical outcome in 
the study presented in Chapter 4 and other studies17 20 It did however not outperform the CURB-65 
score. Also the addition of D-dimer to the CURB-65 score did not improve its performance not by 
improving the AUC or by better reclassification of patients at risk with the Net Reclassification 
Index. The use ofD-dimer as a stand-alone biomarker for prediction of clinical outcome in patients 
with CAP is not useful. Serial measurements of D-dimer levels during treatment did also not add 
any benefit in monitoring the host response. As D-dimer levels are in the mind set of any practicing 
physician correlated with pulmonary embolism and deep venous thrombosis, the use of D-dimer 
levels will probably trigger an increase in radiological diagnostics to rule out any form of venous 
thromboembolism. The levels of serum D-dimer levels are also under influence of the aetiology of 
CAP. The baseline levels of D-dimer in patients with pneumococcal pneumonia is higher than in 
patients with non-pneumococcal pneumonia21• D-dimer levels also rise more during treatment in 
patients with pneumococcal pneumonia. Also older male patients with CAP have higher levels of 
D-dimer levels22• 
CRP under pressure of prednisolone 
The data in presented in chapter 3 of this thesis has significant clinical impact. Several studies has 
shown the usefulness of CRP for diagnosis, assessment of severity or guiding treatment in patients 
with CAP 23·27• By using serial CRP measurements Bruns et al. 24 demonstrated that a reduction in 
CRP levels predicts a clinical good response. Delayed normalisation of CRP levels was associated 
with inappropriate antibiotic therapy. In another study high levels of CRP, next to high levels ofIL-6 
and PCT, on day 3 of treatment was associated with high risk of treatment failure28• None of these 
studies evaluated the use of preadmission or concomitant corticosteroids. Perren et al. 29 found that 
in a group of patient with CAP and COPD (and thus treated with corticosteroids) the reduction of 
CRP during days of treatment was similar to the reduction in those treated without corticosteroids. 
The data on CRP and corticosteroids in the trial by Confalonieri13 and Meijvis1 5 demonstrates quite 
evidently that CRP is influenced by corticosteroids. However the effect on reducing CRP also occurs 
in patients with a clinical failure as demonstrated in this thesis. The widespread using of serial CRP 
measurement for assessing response to treatment can lead to misinterpreting the decline under 
influence of corticosteroids as a good response. PCT is not influenced by prednisolone and should 
therefore by the logical choice for assessing treatment response in patients with CAP who are also 
treated with corticosteroids. The use of PCT to guide treatment in patients with CAP is safe and 
possible cost-effective in terms of reduced antibiotic costs30• 
Anaemia in CAP 
Anaemia plays an important role in the outcome of patients with CAP. The percentage of patients 
with anaemia on admission is up to one-third of the patients and it does have an impact on clinical 
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outcome3 1;32• The pivotal role of hepcidin offers possible intervention strategies. Hepcidin 
concentrations are mediated by IL-6, which by itself can be influenced by corticosteroids14;rn34_ The 
sequestration of iron in the spleen helps to deprive micro-organisms of iron for growth3 5 -37. 
However the iron deficiency under influence ofhepcidin might by a risk factor for negative clinical 
outcomes38. Patients in the ICU with this functional iron deficiency do have comparable APACHE 
II scores but have a longer LOS, duration of ICU stay and a more pro-inflammatory state 39;4o_ 
Several intervention are possible related to the hepcidin pathway, but no clinical data exist in 
patients with CAP 41. 
F U T U R E  P E R S P E CT I V E S 
The way to proceed 
There is an urgent need for improving outcome in patients with CAP. Improvement may come in 
different ways. The first step to improve outcome is to better understand which patients are at risk 
of adverse outcomes. Identification of risk factors is in this light important, especially when these 
risk factors can be influenced. Risk factors as co-morbidities can have a profound impact, or can 
be how paradoxical be protective. Understanding these mechanisms is important to make progress. 
The role of inhaled corticosteroids (ICS) is a good example of better understanding the role of 
COPD as risk factor in CAP. While the use of ICS is associated with increased risk of CAP there 
are several studies implying a possible benefit for patients with CAP who are using ICS42·45. 
Biomarkers such as CRP, PCT and adrenomedullin can help to identify patients with CAP at risk 
for failure and guide treatment. The only biomarker intervention trials in patients with CAP are 
the PCT-guided antibiotic duration of patients with CAP by Christ-Crain et al. 30 and Long et al. 46. 
The pitfalls of biomarker use must also be explored as this may have clinical implications as 
demonstrated in chapter 3 of this thesis. Future trials should focus on biomarker guided 
interventions in patients with CAP. 
The role of anaemia in patients with CAP offers also several possible interventions. The transient 
haemoglobinization arrest under influence of hepcidin observed in chapter 5 and 6 are driven by 
IL-6. Future studies might find beneficial adjunctive therapies aimed at the hepcidin-ferroportin 
axis41. 
Another promising aspect is the role of genetics in CAP. Several studies have examined the risk of 
acquiring CAP or sepsis in the presence of polymorphisms for e.g. ACE or PAI-1 4G/ 5 G47·53 . Also 
polymorphisms in the anti-inflammatory cytokine IL-10 gen are associated with outcome in 
patients with CAP and there are several other polymorphisms (cytokines, coagulation factors) 
associated with outcome in CAP 49;54-5s. 
A causal role for these polymorphisms cannot be ascertained from these observational studies, but 
the possibility of identifying patients with CAP at risk for a poor clinical outcome by analysing 
their genetic make-up is a highly interesting prospect and with the increasing abilities of molecular 
diagnostics it is possible on a large scale. 
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Albert Einstein once said: I never think of the future - it comes soon enough. The future of 
community-acquired pneumonia therapy is bound to change as more individualised treatment 
primed on characteristics of the host response become available for the practicing physician. Some 
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dat <lit proefschrift nu op papier beland is, is mede mogelijk gemaakt door veel mensen. Ik hoop dat 
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Dr W.G. Boersma. Beste Wim, zonder jou zou geen infectieziekten onderzoek mogelijk zijn in 
Alkmaar. Je niet aflatende neiging om steeds maar vooruit te willen gaan is inspirerend. Ook je 
toegankelijkheid en betrokkenheid is fantastisch. Ik weet niet waar je al die tijd voor mij vandaan 
heh gehaald naast je eigen praktijk, werkgroepen, andere onderzoeksprojecten en AZ, maar je 
toegankelijkheid en betrokkenheid is fantastisch. Ik ben je dankbaar voor het creeren van deze 
mogelijkheid voor me en trots dat ik dit proefschrift onder je hoede mocht maken. 
Remco en Martijn, mijn paranimfen, vrienden, Afrika-gangers, mede kroeggangers etc. Dank 
jullie voor jullie steun. Hopelijk biedt dit nu meer ruimte om meer mooie dingen te doen. 
Festivalletje doen? 
Leden van de leescommissie. Prof Dr. M.J. Schultz, Prof Dr. M.J.M. Bonten en Prof Dr H.A.M. 
Kerstjens. Hartelijk dank voor het beoordelen van mijn proefschrift. 
Waar zou ik zijn zonder de gezusters Schoorl? Jullie hebben gezamenlijk veel werk verricht in dat 
gebouw aan de overkant. Dankzij jullie werk hebben we mooie data over biomarkers kunnen 
verzamelen. Ik hoop dat deze samenwerking lang en vruchtbaar zal zijn. 
Dit natuurlijk onder bevlogen leiding van Piet Bartels. Vele nuttige inzichten zijn ontstaan aan jouw 
tafel, die letterlijk altijd overliep met papieren. De "jonge promovendus" is je dankbaar voor alles. 
Verder alle laboranten van het klinisch chemisch lab bedankt voor de zorgvuldigheid waarmee de 
bloedafnames werden gedaan. 
Tijdens mijn onderzoeksperiode heb ik veel ondersteuning gekregen van de afdeling Medische 
Microbiologie zowel in logistieke als in medisch opzicht. Hiervoor wil ik Fer Vlaspolder en Sjaak 
Sloos bedanken, maar ook met name Tineke Tossijn-Groot, mijn microbiologische hulplijn. 
Tjeerd van der Ploeg. Beste Tjeerd je hebt me veilig door het donkere bos van de statistiek geloodst 
met zoveel enthousiasme dat het infectieus is. Met name je hulp bij de NRI berekeningen waren 
fantastisch. 
Verder natuurlijk mijn fantastische collega's in Alkmaar 
Mijn illustere voorgangers en lichtende voorbeelden in Alkmaar, Menno van der Eerden en 
Hans Daniels. Beste Menno, bedankt voor je wijze lessen over pneumonie-onderzoek en voor het 
gebruiken van de data waarmee ik mijn eerste artikel kon schrijven. Data die jij zo keurig in een 
kleine 20 ordners had verzameld. Beste Hans, ere wie ere toekomt, het oorspronkelijke idee van de 
CAPISCE-studie is van jou afkomstig. Ik denk met weemoed terug aan de congresavonturen in San 
Francisco en San Diego. Wat een prachtige wetenschappelijke inzichten hebben we daar op gedaan. 
Mijn medeonderzoekers en assistenten bij de longziekten in Alkmaar, Dewi Tjiong, Josje Altenburg, 
Anna de Boer en Henk-Jan Prins. Onderzoek is leuk maar met meer is het ook nog gezelliger. 
Maarten de Mulder, medeonderzoeker maar dan aan dat andere orgaan in de thorax. Dank je voor 
je hulp, het "sparren" van ideeen en het meedenken over van alles. Succes met je eigen 
promotietraject. En natuurlijk de overige assistenten ten tijde van mijn onderzoeksperiode Kasper, 
Laurien, Laurence, Martijn, Fredrike, Sayed, Funda, Gea, Yeun-Ying en Gwendolyn. Dank jullie 
voor jullie inzet om mijn studie goed te laten lopen. 
Ik heb veel te danken aan de maatschap longziekten in Alkmaar. Niet alleen voor de mogelijkheden 
om onderzoek te doen, maar ook voor een prachtige opleidingsplaats. 
Jan van de Bergh, beste Jan bedankt dat je altijd klaar stond voor je assistenten. Je zei tegen mij toen 
het eerste volledig geschreven protocol was afgewezen en mijn hoofd enigszins begon te hangen: 
"het komt wel goed, kost alleen wat tijd': In beide had je gelijk. 
Casper de Graaf, beste Cas, dank je voor de ondersteuning tijdens mijn onderzoeksperiode. Je 
deur stond altijd open voor vragen en je rode pen was altijd klaar om mijn Engels aan te 
scherpen. 
De overige longartsen ten tijde van mijn onderzoeksperiode, Joost van den Aardweg, Alle Welling 
en Tjeerd Haitjema,. Dank je voor de ruimte die jullie hebben geboden aan mij om dit onderzoek 
te mogen doen. Jullie steun, en jullie opbouwende kritiek, is mij zeer dankbaar en waardevol. 
Ook de verpleegkundigen op de longafdeling, intensive care, interne afdeling en de SEH wil ik 
graag bedanken voor de hulp bij het uitvoering van deze studie. Zonder jullie bereidwillig om wat 
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extra's te doen was deze studie niet uitvoerbaar. Darien en Deliana, super-secretaressen, dank jullie 
voor jullie hulp bij de logistieke zaken van de studie-patienten. 
Natuurlijk wil ik alle patienten en betrokken familieleden bedanken voor het meedoen aan een 
studie. 
Lieve Paps, helaas hen je er niet meer bij voor <lit laatste stukje. Waarschijnlijk had je toch allemaal 
een enorme poespas en poppenkast gevonden, maar ik had je erg zo graag bijgehad. 
Lieve Mams, het was een zware periode voor je. Hopelijk wordt het vaarwater allemaal wat rustiger 
nu. Dank je, voor je steun samen met papa tijdens mijn studie, opleiding en onderzoek. 
Lieve Marloes, het werk is eindelijk af. Ik weet niet hoe je het hebt volgehouden als ik weer eens 
bezig was met schrijven, statistiek, presentaties maken, congresbezoek ("het is dan wel in San 
Francisco, maar het is gewoon werk, hoor!") e.d. Vanaf nu meer tijd voor je, samen met onze twee 
schatjes. Kan niet wachten. 
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CU R R I CU L U M  V ITAE 
Dominic Snijders was born on the 16th of February 1978 in Bovenkarspel. He graduated from 
Werenfridus high school in 1996, after which he studied chemistry at the VU university in 
Amsterdam. In 1997 he was admitted to the study of medicine at the VU university. He attained 
his masters degree in 2002 and finished internships in 2004 with a profile in heart and vasculair 
diseases. His scientific thesis on quantitative analysis of myocardial FDG PET studies. During his 
study he supervised medical and biomedical students during chemisty courses. In 2005 he started 
on the research project which resulted in this thesis. In 2008 he started his specialist training 
internal medicine in Alkmaar (Dr F. Stam). In 2010 he continued his specialist training in 
pulmonary medicine in Alkmaar (Dr. J.G. van den Aardweg). He will finish his training January 
2013. He lives in Berkhout, together with Marloes Zomer and their two sons, Thijmen en Brent. 
Dominic Snijders werd geboren op 16 februari 1978 in Bovenkarspel. Hij behaalde zijn eindexamen 
gymnasium in 1996 aan het Werenfridus scholengemeenschap in Hoorn. Hierna ging hij 
Scheikunde studeren aan de VU in Amsterdam, nadat hij was uitgeloot voor geneeskunde. In 1997 
werd hij ingeloot voor de studie geneeskunde. Hij behaalde zijn doctoraal geneeskunde in 2002 en 
zijn artsenbul in 2004. Zijn afstudeerprofiel was hart- en vaatziekten en zijn wetenschappelijke 
stage was over quantitative analysis of myocardial FDG PET studies. Tijdens zijn studieperiode 
heeft hij studenten geneeskunde en medische biologie begeleidt bij het vak medisch chemie. In 
2005 is hij begonnen met zijn promotieonderzoek in het Medisch Centrum Alkmaar waarvan de 
resultaten in <lit proefschrift staan beschreven. In 2008 startle hij met zijn vooropleiding interne 
geneeskunde in het medisch Centrum Alkmaar (Opleider Dr. F. Stam). In 2010 vervolgde hij zijn 
opleiding tot longarts in Medisch centrum Alkmaar (opleider Dr. J.G. van den Aardweg). Hij zal 
zijn opleiding per 1 januari 2013 voltooien. Hij woont in Berkhout samen met Marloes Zomer, 
samen met hun twee zonen Thijmen en Brent. 
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